




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 263/58, 413/12, A61K 31/42 // (C07D 413/12, 263:00, 263:00)		A1	(11) International Publication Number: WO 00/68213 (43) International Publication Date: 16 November 2000 (16.11.00)
(21) International Application Number: PCT/GB00/01731 (22) International Filing Date: 5 May 2000 (05.05.00) (30) Priority Data: 9910394.7 5 May 1999 (05.05.99) GB 60/141,471 29 June 1999 (29.06.99) US (71) Applicant (for all designated States except US): AVENTIS PHARMA LIMITED [GB/GB]; Aventis House, Kings Hill, 50 Kings Hill Avenue, West Malling, Kent ME19 4AH (GB). (72) Inventors; and (75) Inventors/Applicants (for US only): CLARK, David, Edward [GB/GB]; Aventis Pharma Limited, Rainham Road South, Dagenham, Essex RM10 7XS (GB). EASTWOOD, Paul, Robert [GB/GB]; Aventis Pharma Limited, Rainham Road South, Dagenham, Essex RM10 7XS (GB). HARRIS, Neil, Victor [GB/GB]; Aventis Pharma Limited, Rainham Road South, Dagenham, Essex RM10 7XS (GB). MCCARTHY, Clive [GB/GB]; Aventis Pharma Limited, Rainham Road South, Dagenham, Essex RM10 7XS (GB). MORLEY, Andrew, David [GB/GB]; Aventis Pharma Limited, Rainham Road South, Dagenham, Essex RM10 7XS (GB). PICKETT,		Stephen, Dennis [GB/GB]; Aventis Pharma Limited, Rainham Road South, Dagenham, Essex RM10 7XS (GB). (74) Agent: CAFFIN, Lee; Aventis Pharma Limited, Rainham Road South, Dagenham, Essex RM10 7XS (GB). (81) Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
		Published With international search report.	

(54) Title: SUBSTITUTED BICYCLIC COMPOUNDS



(57) Abstract

The invention is directed to physiologically active compounds of general formula (I): wherein Het is an optionally substituted, saturated, partially saturated or fully unsaturated 8 to 10 membered bicyclic ring system containing at least one heteroatom selected from O, S or N; R¹ is optionally substituted aryl, heteroaryl, alkyl, alkenyl, alkynyl, cycloalkyl or heterocycloalkyl; R² is hydrogen, halogen, lower alkyl or lower alkoxy; Z¹ is NR⁵; L¹ is a -R⁶-R⁷- linkage (where R⁶ is alkylene, alkenylene or alkynylene and R⁷ is a direct bond, cycloalkylene, heterocycloalkylene, arylidyl, heteroarylidy, -C(=Z³)-NR⁵-, -NR⁵-C(=Z³)-, -Z³-, -C(=O)-, -C(=NOR⁵)-, -NR⁵-, -NR⁵-C(=Z³)-NR⁵-, -SO₂-NR⁵-, -NR⁵-SO₂-, -O-C(=O)-, -C(=O)-O-, -NR⁵-C(=O)-O- or -O-C(=O)-NR⁵-); L² is an alkylene chain substituted by hydroxy, oxo, -OR⁴, -O-C(=O)-R⁴, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹, -N(R⁸)-SO₂-R⁹, or -NY³ Y⁴; and Y is carboxy or an acid bioisostere; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (α4β1)

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZV	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

SUBSTITUTED BICYCLIC COMPOUNDS

This invention is directed to substituted bicyclic compounds, their preparation, pharmaceutical compositions containing these compounds, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of cell adhesion.

Cell adhesion is a process by which cells associate with each other, migrate towards a specific target or localise within the extra-cellular matrix. Many of the cell-cell and cell-extracellular matrix interactions are mediated by protein ligands (e.g. fibronectin, VCAM-1 and vitronectin) and their integrin receptors [e.g. $\alpha 5 \beta 1$ (VLA-5), $\alpha 4 \beta 1$ (VLA-4) and $\alpha V \beta 3$]. Recent studies have shown these interactions to play an important part in many physiological (e.g. embryonic development and wound healing) and pathological conditions (e.g. tumour-cell invasion and metastasis, inflammation, atherosclerosis and autoimmune disease).

A wide variety of proteins serve as ligands for integrin receptors. In general, the proteins recognised by integrins fall into one of three classes: extracellular matrix proteins, plasma proteins and cell surface proteins. Extracellular matrix proteins such as collagen fibronectin, fibrinogen, laminin, thrombospondin and vitronectin bind to a number of integrins. Many of the adhesive proteins also circulate in plasma and bind to activated blood cells. Additional components in plasma that are ligands for integrins include fibrinogen and factor X. Cell bound complement C3bi and several transmembrane proteins, such as Ig-like cell adhesion molecule (ICAM-1,2,3) and vascular cell adhesion molecule (VCAM-1), which are members of the Ig superfamily, also serve as cell-surface ligands for some integrins.

Integrins are heterodimeric cell surface receptors consisting of two subunits called α and β . There are at least fifteen different α -subunits ($\alpha 1$ - $\alpha 9$, α -L, α -M, α -X, α -IIb, α -V and α -E) and at least seven different β ($\beta 1$ - $\beta 7$) subunits. The integrin family can be subdivided into classes based on the β subunits, which can be associated with one or more α -subunits. The most widely distributed integrins belong to the $\beta 1$ class, also known as the very late antigens (VLA). The second class of integrins are leukocyte specific receptors and consist of one of three α -subunits (α -L, α -M or α -X) complexed with the $\beta 2$ protein. The cytoadhesins α -IIb $\beta 3$ and α -V $\beta 3$, constitute the third class of integrins.

The present invention principally relates to agents which modulate the interaction of the ligand VCAM-1 with its integrin receptor $\alpha 4 \beta 1$ (VLA-4), which is expressed on numerous


hematopoietic cells and established cell lines, including hematopoietic precursors, peripheral and cytotoxic T lymphocytes, B lymphocytes, monocytes, thymocytes and eosinophils.

The integrin $\alpha 4 \beta 1$ mediates both cell-cell and cell-matrix interactions. Cells expressing $\alpha 4 \beta 1$ bind to the carboxy-terminal cell binding domain (CS-1) of the extracellular matrix protein fibronectin, to the cytokine-inducible endothelial cell surface protein VCAM-1, and to each other to promote homotypic aggregation. The expression of VCAM-1 by endothelial cells is upregulated by proinflammatory cytokines such as INF- γ , TNF- α , IL-1 β and IL-4.

Regulation of $\alpha 4 \beta 1$ mediated cell adhesion is important in numerous physiological processes, including T-cell proliferation, B-cell localisation to germinal centres, and adhesion of activated T-cells and eosinophils to endothelial cells. Evidence for the involvement of VLA-4/VCAM-1 interaction in various disease processes such as melanoma cell division in metastasis, T-cell infiltration of synovial membranes in rheumatoid arthritis, autoimmune diabetes, colitis and leukocyte penetration of the blood-brain barrier in experimental autoimmune encephalomyelitis, atherosclerosis, peripheral vascular disease, cardiovascular disease and multiple sclerosis, has been accumulated by investigating the role of the peptide CS-1 (the variable region of fibronectin to which $\alpha 4 \beta 1$ binds via the sequence Leu-Asp-Val) and antibodies specific for VLA-4 or VCAM-1 in various in vitro and in vivo experimental models of inflammation. For example, in a Streptococcal cell wall-induced experimental model of arthritis in rats, intravenous administration of CS-1 at the initiation of arthritis suppresses both acute and chronic inflammation (S.M.Wahl et al., J.Clin.Invest., 1994, 94, pages 655-662). In the oxazolone-sensitised model of inflammation (contact hypersensitivity response) in mice, intravenous administration of anti- $\alpha 4$ specific monoclonal antibodies significantly inhibited (50-60% reduction in the ear swelling response) the efferent response (P.L.Chisholm et al. J.Immunol., 1993, 23, pages 682-688). In a sheep model of allergic bronchoconstriction, HP1/2, an anti- $\alpha 4$ monoclonal antibody given intravenously or by aerosol, blocked the late response and the development of airway hyperresponsiveness (W.M. Abraham et al. J. Clin. Invest., 1994, 93 pages 776-787).

We have now found a novel group of substituted bicyclic compounds which have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 ($\alpha 4 \beta 1$).

Thus, in one aspect, the present invention is directed to compounds of general formula (I):-



5 wherein:-

Het represents a saturated, partially saturated or fully unsaturated 8 to 10 membered bicyclic ring system containing at least one heteroatom selected from O, S or N, optionally substituted by one or more aryl group substituents;

10 R¹ represents aryl, heteroaryl, optionally substituted alkyl, alkenyl or alkynyl where each is optionally substituted by R³, -Z²R⁴, -Z³H, -C(=O)-R⁴, -NR⁵-C(=Z³)-R⁴, -NR⁵-C(=O)-OR⁴, -NR⁵-SO₂-R⁴, -SO₂-NY¹Y², -NY¹Y² or -C(=Z³)-NY¹Y²; or cycloalkyl or heterocycloalkyl, each optionally substituted by R⁴, -Z²R⁴, -Z³H, -C(=O)-R⁴, -NR⁵-C(=Z³)-R⁴, -NR⁵-C(=O)-OR⁴, -NR⁵-SO₂-R⁴, -SO₂-NY¹Y², -NY¹Y² or -C(=Z³)-NY¹Y²;

R² represents hydrogen, halogen, lower alkyl or lower alkoxy;

15 R³ represents aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycloalkyl;

R⁴ represents alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocycloalkyl or heterocycloalkylalkyl;

R⁵ represents hydrogen or lower alkyl;

20 R⁶ is an alkylene chain, an alkenylene chain or an alkynylene chain;

R⁷ is a direct bond, cycloalkylene, heterocycloalkylene, aryldiyl, heteroaryldiyl, -C(=Z³)-NR⁵-, -NR⁵-C(=Z³)-, -Z³-, -C(=O)-, -C(=NOR⁵)-, -NR⁵-, -NR⁵-C(=Z³)-NR⁵-, -SO₂-NR⁵-, -NR⁵-SO₂-, -O-C(=O)-, -C(=O)-O-, -NR⁵-C(=O)-O- or -O-C(=O)-NR⁵-;

25 R⁸ is hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;

R⁹ is alkyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, or alkyl substituted by aryl, an acidic functional group or corresponding protected derivative, cycloalkyl, heteroaryl, heterocycloalkyl, -Z³H, -Z²R⁴, -C(=O)-NY³Y⁴ or -NY³Y⁴;

L¹ represents a -R⁶-R⁷- linkage;

L² represents an alkylene chain substituted by hydroxy, oxo, -OR⁴, -O-C(=O)-R⁴, -N(R⁸)-C(=O)-R⁹, -N(R⁸)-C(=O)-OR⁹, -N(R⁸)-SO₂-R⁹, or -NY³Y⁴;

Y is carboxy or an acid bioisostere;

Y¹ and Y² are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group -NY¹Y² may form a cyclic amine;

Y³ and Y⁴ are independently hydrogen, alkenyl, alkyl, alkynyl, aryl, cycloalkenyl, cycloalkyl, heteroaryl, heterocycloalkyl, or alkyl substituted by alkoxy, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, hydroxy, oxo, -NY¹Y², or one or more -CO₂R⁸ or -C(=O)-NY¹Y² groups; or

the group -NY³Y⁴ may form a cyclic amine;

Z¹ represents NR⁵;

Z² is O or S(O)_n;

Z³ is O or S; and

n is zero or an integer 1 or 2;

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs; but excluding compounds where an oxygen, nitrogen or sulphur atom is attached directly to a carbon carbon multiple bond of an alkenyl or alkynyl residue.

In the present specification, the term "compounds of the invention", and equivalent expressions, are meant to embrace compounds of general formula (I) as hereinbefore described, which expression includes the prodrugs, the pharmaceutically acceptable salts, and the solvates, e.g. hydrates, where the context so permits. Similarly, reference to intermediates, whether or not they themselves are claimed, is meant to embrace their salts, and solvates, where the context so permits. For the sake of clarity, particular instances when the context so permits are sometimes indicated in the text, but these instances are purely illustrative and it is not intended to exclude other instances when the context so permits.

As used above, and throughout the description of the invention, the following terms, unless otherwise indicated, shall be understood to have the following meanings:-

"Patient" includes both human and other mammals.

"Acid bioisostere" means a group which has chemical and physical similarities producing broadly similar biological properties to a carboxy group (see Lipinski, Annual Reports in Medicinal Chemistry, 1986,21,p283 "Bioisosterism In Drug Design"; Yun, Hwahak Sekye, 1993,33,p576-579 "Application Of Bioisosterism To New Drug Design"; Zhao, Huaxue Tongbao, 1995,p34-38 "Bioisosteric Replacement And Development Of Lead Compounds In Drug Design"; Graham, Theochem, 1995,343,p105-109 "Theoretical Studies Applied To Drug Design:ab initio Electronic Distributions In Bioisosteres"). Examples of suitable acid bioisosteres include: -C(=O)-NHOH, -C(=O)-CH₂OH, -C(=O)-CH₂SH, -C(=O)-NH-CN, sulpho, phosphono, alkylsulphonylcarbamoyl, tetrazolyl, arylsulphonylcarbamoyl, heteroarylsulphonylcarbamoyl, N-methoxycarbamoyl, 3-hydroxy-3-cyclobutene-1,2-dione, 3,5-dioxo-1,2,4-oxadiazolidinyl or heterocyclic phenols such as 3-hydroxyisoxazolyl and 3-hydroxy-1-methylpyrazolyl.

"Acidic functional group" means a group with an acidic hydrogen within it. The "corresponding protected derivatives" are those where the acidic hydrogen atom has been replaced with a suitable protecting group. For suitable protecting groups see T.W. Greene and P.G.M. Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991. Exemplary acidic functional groups include carboxyl (and acid bioisosteres), hydroxy, mercapto and imidazole. Exemplary protected derivatives include esters of carboxy groups, ethers of hydroxy groups, thioethers of mercapto groups and N-benzyl derivatives of imidazoles.

"Acyl" means an H-CO- or alkyl-CO- group in which the alkyl group is as described herein.

"Acylamino" is an acyl-NH- group wherein acyl is as defined herein.

"Alkenyl" means an aliphatic hydrocarbon group containing a carbon-carbon double bond and which may be straight or branched having about 2 to about 15 carbon atoms in the chain. Preferred alkenyl groups have 2 to about 12 carbon atoms in the chain; and more preferably 2 to about 6 carbon atoms (e.g. 2 to 4 carbon atoms) in the chain. "Branched", as used herein and throughout the text, means that one or more lower alkyl groups such as methyl, ethyl or propyl are attached to a linear chain; here a linear alkenyl chain. "Lower alkenyl" means about 2 to about 4 carbon atoms in the chain which may be straight or branched. Exemplary alkenyl groups include ethenyl, propenyl, n-butenyl, i-butenyl, 3-methylbut-2-enyl, n-pentenyl, heptenyl, octenyl, cyclohexylbutenyl and decenyl.

"Alkenylene" means an aliphatic bivalent radical derived from a straight or branched alkenyl group, in which the alkenyl group is as described herein. Exemplary alkenylene radicals include vinylene and propylene.

- 5 "Alkoxy" means an alkyl-O- group in which the alkyl group is as described herein. Exemplary alkoxy groups include methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy and heptoxy.

"Alkoxycarbonyl" means an alkyl-O-CO- group in which the alkyl group is as described herein. Exemplary alkoxycarbonyl groups include methoxy- and ethoxycarbonyl.

10

"Alkyl" means, unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched having about 1 to about 15 carbon atoms in the chain optionally substituted by alkoxy or by one or more halogen atoms. Particular alkyl groups have from 1 to about 6 carbon atoms. "Lower alkyl" as a group or part of a lower alkoxy, lower alkylthio,
15 lower alkylsulphinyl or lower alkylsulphonyl group means unless otherwise specified, an aliphatic hydrocarbon group which may be straight or branched having 1 to about 4 carbon atoms in the chain. Exemplary alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, 3-pentyl, heptyl, octyl, nonyl, decyl and dodecyl.

- 20 "Alkylene" means an aliphatic bivalent radical derived from a straight or branched alkyl group, in which the alkyl group is as described herein. Exemplary alkylene radicals include methylene, ethylene and trimethylene.

"Alkylenedioxy" means an -O-alkylene-O- group in which alkylene is as defined above.

- 25 Exemplary alkylenedioxy groups include methylenedioxy and ethylenedioxy.

"Alkylsulphinyl" means an alkyl-SO- group in which the alkyl group is as previously described. Preferred alkylsulphinyl groups are those in which the alkyl group is C₁₋₄alkyl.

- 30 "Alkylsulphonyl" means an alkyl-SO₂- group in which the alkyl group is as previously described. Preferred alkylsulphonyl groups are those in which the alkyl group is C₁₋₄alkyl.

- "Alkylsulphonylcarbamoyl" means an alkyl-SO₂-NH-C(=O)- group in which the alkyl group is as previously described. Preferred alkylsulphonylcarbamoyl groups are those in which the alkyl
35 group is C₁₋₄alkyl.

"Alkylthio" means an alkyl-S- group in which the alkyl group is as previously described. Exemplary alkylthio groups include methylthio, ethylthio, isopropylthio and heptylthio.

5 "Alkynyl" means an aliphatic hydrocarbon group containing a carbon-carbon triple bond and which may be straight or branched having about 2 to about 15 carbon atoms in the chain. Preferred alkynyl groups have 2 to about 12 carbon atoms in the chain; and more preferably 2 to about 6 carbon atoms (e.g. 2 to 4 carbon atoms) in the chain. Exemplary alkynyl groups include ethynyl, propynyl, n-butynyl, i-butynyl, 3-methylbut-2-ynyl, and n-pentynyl.

10

"Alkynylene" means an aliphatic bivalent radical derived from a straight or branched alkynyl group, in which the alkynyl group is as described herein. Exemplary alkynylene radicals include ethynylene and propynylene.

15 "Aroyl" means an aryl-CO- group in which the aryl group is as described herein. Exemplary aroyl groups include benzoyl and 1- and 2-naphthoyl.

"Aroylamino" is an aroyl-NH- group wherein aroyl is as previously defined.

20 "Aryl" as a group or part of a group denotes: (i) an optionally substituted monocyclic or multicyclic aromatic carbocyclic moiety of about 6 to about 14 carbon atoms, such as phenyl or naphthyl; or (ii) an optionally substituted partially saturated multicyclic aromatic carbocyclic moiety in which an aryl and a cycloalkyl or cycloalkenyl group are fused together to form a cyclic structure, such as a tetrahydronaphthyl, indenyl or indanyl ring. Aryl groups may be substituted with one or more aryl group substituents which may be the same or different, where
 25 "aryl group substituent" includes, for example, acyl, acylamino, alkoxy, alkoxycarbonyl, alkylenedioxy, alkylsulphinyl, alkylsulphonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulphinyl, arylsulphonyl, arylthio, carboxy, cyano, halo, heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, hydroxy, nitro, trifluoromethyl, Y^1Y^2N- , Y^1Y^2NCO- , $Y^1Y^2NSO_2-$,
 30 $Y^1Y^2N-C_{2-6}alkylene-Z-$ [where Z is O, NR^5 or $S(O)_n$], $alkylC(=O)-Y^1N-$, $alkylSO_2-Y^1N-$ or alkyl optionally substituted with aryl, heteroaryl, hydroxy, or Y^1Y^2N- . When R^1 is an optionally substituted aryl group, this may particularly represent optionally substituted phenyl.

"Arylalkenyl" means an aryl-alkenyl- group in which the aryl and alkenyl are as previously described. Preferred arylalkenyls contain a lower alkenyl moiety. Exemplary arylalkenyl groups include styryl and phenylallyl.

5 "Arylalkyl" means an aryl-alkyl- group in which the aryl and alkyl moieties are as previously described. Preferred arylalkyl groups contain a C₁₋₄alkyl moiety. Exemplary arylalkyl groups include benzyl, 2-phenethyl and naphthalenemethyl.

10 "Arylalkyloxy" means an arylalkyl-O- group in which the arylalkyl groups is as previously described. Exemplary arylalkyloxy groups include benzyloxy and 1- or 2-naphthalenemethoxy.

"Arylalkyloxycarbonyl" means an arylalkyl-O-CO- group in which the arylalkyl groups is as previously described. An exemplary arylalkyloxycarbonyl group is benzyloxycarbonyl.

15 "Arylalkylthio" means an arylalkyl-S- group in which the arylalkyl group is as previously described. An exemplary arylalkylthio group is benzylthio.

"Arylalkynyl" means an aryl-alkynyl- group in which the aryl and alkynyl are as previously described. Exemplary arylalkynyl groups include phenylethynyl and 3-phenylbut-2-ynyl.

20

"Aryldiyl" means an optionally substituted bivalent radical derived from an aryl group. Exemplary aryldiyl groups include optionally substituted phenylene, naphthylene and indanylene. Suitable substituents include one or more "aryl group substituents" as defined above, particularly halogen, methyl or methoxy.

25

"Aryloxy" means an aryl-O- group in which the aryl group is as previously described. Exemplary aryloxy groups include optionally substituted phenoxy and naphthoxy.

30 "Aryloxycarbonyl" means an aryl-O-C(=O)- group in which the aryl group is as previously described. Exemplary aryloxycarbonyl groups include phenoxycarbonyl and naphthoxycarbonyl.

"Arylsulphinyl" means an aryl-SO- group in which the aryl group is as previously described.

35 "Arylsulphonyl" means an aryl-SO₂- group in which the aryl group is as previously described.

"Arylsulphonylcarbamoyl" means an aryl-SO₂-NH-C(=O)- group in which the aryl group is as previously described.

5 "Arylthio" means an aryl-S- group in which the aryl group is as previously described.
Exemplary arylthio groups include phenylthio and naphthylthio.

10 "Cyclic amine" means a 3 to 8 membered monocyclic cycloalkyl ring system where one of the ring carbon atoms is replaced by nitrogen and which (i) may be optionally substituted with one or more substituents selected from alkoxy, carboxamido, carboxy, hydroxy, oxo (or a 5-, 6- or 7-membered cyclic acetal derivative thereof) or R⁹; (ii) may also contain a further heteroatom selected from O, S, SO₂, or NY⁵ (where Y⁵ is hydrogen, alkyl, aryl, arylalkyl, -C(=O)-R¹⁰, -C(=O)-OR¹⁰ or -SO₂R¹⁰ and R¹⁰ is alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl); and (iii) may be fused to
15 additional aryl (e.g. phenyl), heteroaryl (e.g. pyridyl), heterocycloalkyl or cycloalkyl rings to form a bicyclic or tricyclic ring system. Exemplary cyclic amines include pyrrolidine, piperidine, morpholine, piperazine, indoline, pyrindoline, tetrahydroquinoliny and the like groups.

20 "Cycloalkenyl" means a non-aromatic monocyclic or multicyclic ring system containing at least one carbon-carbon double bond and having about 3 to about 10 carbon atoms. Exemplary monocyclic cycloalkenyl rings include cyclopentenyl, cyclohexenyl or cycloheptenyl.

"Cycloalkenylalkyl" means a cycloalkenyl-alkyl- group in which the cycloalkenyl and alkyl moieties are as previously described. Exemplary cycloalkenylalkyl groups include
25 cyclopentenylmethyl, cyclohexenylmethyl or cycloheptenylmethyl.

"Cycloalkyl" means a saturated monocyclic or bicyclic ring system of about 3 to about 10 carbon atoms optionally substituted by oxo. Exemplary monocyclic cycloalkyl rings include C₃₋₈cycloalkyl rings such as cyclopropyl, cyclopentyl, cyclohexyl and cycloheptyl.

30 "Cycloalkylalkyl" means a cycloalkyl-alkyl- group in which the cycloalkyl and alkyl moieties are as previously described. Exemplary monocyclic cycloalkylalkyl groups include cyclopropylmethyl, cyclopentylmethyl, cyclohexylmethyl and cycloheptylmethyl.

"Cycloalkylene" means a bivalent radical derived from a cycloalkyl group.

"Halo" or "halogen" means fluoro, chloro, bromo, or iodo. Preferred are fluoro or chloro.

5 "Heteroaroyl" means a heteroaroyl-C(=O)- group in which the heteroaroyl group is as described herein. Exemplary groups include pyridylcarbonyl.

"Heteroaroylamino" means a heteroaroyl-NH- group in which the heteroaroyl moiety are as previously described.

10

"Heteroaryl" as a group or part of a group denotes: (i) an optionally substituted aromatic monocyclic or multicyclic organic moiety of about 5 to about 10 ring members in which one or more of the ring members is/are element(s) other than carbon, for example nitrogen, oxygen or sulphur (examples of such groups include benzimidazolyl, benzthiazolyl, furyl, imidazolyl, 15 indolyl, indoliziny, isoxazolyl, isoquinoliny, isothiazolyl, oxadiazolyl, pyraziny, pyridaziny, pyrazolyl, pyridyl, pyrimidiny, pyrroly, quinazoliny, quinoliny, 1,3,4-thiadiazolyl, thiazolyl, thienyl and triazolyl groups, optionally substituted by one or more aryl group substituents as defined above); (ii) an optionally substituted partially saturated multicyclic heterocarbocyclic moiety in which a heteroaryl and a cycloalkyl or cycloalkenyl group are fused together to form a 20 cyclic structure (examples of such groups include pyrindanyl groups). Optional substituents include one or more "aryl group substituents" as defined above.

"Heteroarylalkenyl" means a heteroaryl-alkenyl- group in which the heteroaryl and alkenyl moieties are as previously described. Preferred heteroarylalkenyl groups contain a lower 25 alkenyl moiety. Exemplary heteroarylalkenyl groups include pyridylethenyl and pyridylallyl.

"Heteroarylalkyl" means a heteroaryl-alkyl- group in which the heteroaryl and alkyl moieties are as previously described. Preferred heteroarylalkyl groups contain a C₁₋₄alkyl moiety. Exemplary heteroarylalkyl groups include pyridylmethyl.

30

"Heteroarylalkyloxy" means an heteroarylalkyl-O- group in which the heteroarylalkyl group is as previously described. Exemplary heteroaryloxy groups include optionally substituted pyridylmethoxy.

"Heteroarylalkynyl" means a heteroaryl-alkynyl- group in which the heteroaryl and alkynyl moieties are as previously described. Exemplary heteroarylalkenyl groups include pyridylethynyl and 3-pyridylbut-2-ynyl.

5 "Heteroaryldiyl" means a bivalent radical derived from a heteroaryl group.

"Heteroaryloxy" means an heteroaryl-O- group in which the heteroaryl group is as previously described. Exemplary heteroaryloxy groups include optionally substituted pyridyloxy.

10 "Heteroarylsulphonylcarbamoyl" means a heteroaryl-SO₂-NH-C(=O)- group in which the heteroaryl group is as previously described.

"Heterocycle" denotes an optionally substituted saturated, partially saturated or fully unsaturated monocyclic organic moiety of 5 or 6 ring members in which one or more of the ring members is/are element(s) other than carbon, for example nitrogen, oxygen or sulphur. Exemplary 5 or 6 membered heterocycles include furyl, imidazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, oxazolyl, oxazinyl, piperidinyl, pyrazinyl, pyridazinyl, pyrazolyl, pyridyl, pyrimidinyl, pyrrolyl, pyrrolidinyl, pyrrolinyl, 1,3,4-thiadiazolyl, thiazolyl, thienyl and triazolyl groups. Optional substituents include one or more "aryl group substituents" as defined above.

20 "Heterocycloalkyl" means: (i) a cycloalkyl group of about 3 to 7 ring members which contains one or more heteroatoms selected from O, S or NY⁵ and optionally substituted by oxo; (ii) a partially saturated multicyclic heterocarbocyclic moiety in which an aryl (or heteroaryl ring), each optionally substituted by one or more "aryl group substituents", and a heterocycloalkyl group are fused together to form a cyclic structure (examples of such groups include chromanyl, dihydrobenzofuranyl, indoliny and pyrindoliny groups).

25 "Heterocycloalkylalkyl" means a heterocycloalkyl-alkyl- group in which the heterocycloalkyl and alkyl moieties are as previously described.

30

"Heterocycloalkylene" means a bivalent radical derived from a heterocycloalkyl group.

"Prodrug" means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of formula (I), including N-oxides thereof. For example an ester of a compound of formula (I) containing a hydroxy group may be convertible by hydrolysis in vivo to

35

the parent molecule. Alternatively an ester of a compound of formula (I) containing a carboxy group may be convertible by hydrolysis in vivo to the parent molecule.

Suitable esters of compounds of formula (I) containing a hydroxy group, are for example
5 acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis- β -hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates, methanesulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates and quinates.

10 Suitable esters of compounds of formula (I) containing a carboxy group, are for example those described by F.J.Leinweber, Drug Metab. Res., 1987, 18, page 379.

An especially useful class of esters of compounds of formula (I) containing a hydroxy group, may be formed from acid moieties selected from those described by Bundgaard et. al., J. Med. Chem.,
15 1989, 32, page 2503-2507, and include substituted (aminomethyl)-benzoates, for example dialkylamino-methylbenzoates in which the two alkyl groups may be joined together and/or interrupted by an oxygen atom or by an optionally substituted nitrogen atom, e.g. an alkylated nitrogen atom, more especially (morpholino-methyl)benzoates, e.g. 3- or
4-(morpholinomethyl)-benzoates, and (4-alkylpiperazin-1-yl)benzoates, e.g. 3- or
20 4-(4-alkylpiperazin-1-yl)benzoates.

Where the compound of the invention contains a carboxy group, or a sufficiently acidic bioisostere, base addition salts may be formed and are simply a more convenient form for use; and in practice, use of the salt form inherently amounts to use of the free acid form. The bases
25 which can be used to prepare the base addition salts include preferably those which produce, when combined with the free acid, pharmaceutically acceptable salts, that is, salts whose cations are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base are not vitiated by side effects ascribable to the cations.

Pharmaceutically acceptable salts, including those derived from alkali and alkaline earth metal
30 salts, within the scope of the invention include those derived from the following bases: sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminium hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide, ammonia, ethylenediamine, N-methyl-glucamine, lysine, arginine, ornithine, choline,
N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine,
35 N-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)aminomethane, tetramethylammonium hydroxide, and the like.

Some of the compounds of the present invention are basic, and such compounds are useful in the form of the free base or in the form of a pharmaceutically acceptable acid addition salt thereof.

5 Acid addition salts are a more convenient form for use; and in practice, use of the salt form inherently amounts to use of the free base form. The acids which can be used to prepare the acid addition salts include preferably those which produce, when combined with the free base, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free
10 base are not vitiated by side effects ascribable to the anions. Although pharmaceutically acceptable salts of said basic compounds are preferred, all acid addition salts are useful as sources of the free base form even if the particular salt, per se, is desired only as an intermediate product as, for example, when the salt is formed only for purposes of purification, and identification, or when it is used as intermediate in preparing a pharmaceutically acceptable salt
15 by ion exchange procedures. Pharmaceutically acceptable salts within the scope of the invention include those derived from mineral acids and organic acids, and include hydrohalides, e.g. hydrochlorides and hydrobromides, sulphates, phosphates, nitrates, sulphamates, acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, methylene-bis-b-hydroxynaphthoates, gentisates, isethionates, di-p-toluoyltartrates,
20 methane-sulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphamates and quinates.

As well as being useful in themselves as active compounds, salts of compounds of the invention are useful for the purposes of purification of the compounds, for example by exploitation of the
25 solubility differences between the salts and the parent compounds, side products and/or starting materials by techniques well known to those skilled in the art.

With reference to formula (I) above, the following are particular and preferred groupings:

30 R^1 may particularly represent optionally substituted aryl, especially optionally substituted phenyl.




R^1 may also particularly represent optionally substituted heteroaryl.

35 R^1 may also particularly represent arylalkyl (e.g. benzyl and phenethyl).


R^1 may also particularly represent cycloalkyl (e.g. cyclohexyl).


Z^1 may particularly represent NH.

5





Het may particularly represent , wherein ring  is a 5 or 6 membered heterocycle and ring  is a 5 or 6 membered heterocycle or a benzene ring, each ring optionally substituted by one or more "aryl group substituents" as defined above, and the two rings are joined together by a carbon-carbon linkage or a carbon-nitrogen linkage.

10




Ring  may particularly represent a 5 membered fully unsaturated heterocycle, optionally substituted by one or more "aryl group substituents" as defined above.

Ring  may particularly represent a benzene ring, optionally substituted by one or more "aryl group substituents" as defined above.

15

 may particularly represent a 9 membered bicyclic system in which rings  and  are as defined just above and the two rings are joined together by carbon atom linkages.  is preferably optionally substituted benzimidazolyl or, more preferably, optionally substituted benzoxazolyl.

20

Each of rings  and , but more particularly ring , may be substituted

by one or more "aryl group substituents" as defined above [examples of particular aryl group substituents include lower alkyl (e.g. methyl), lower alkoxy (e.g. methoxy), amino, halogen, hydroxy, lower alkylthio, lower alkylsulphinyl, lower alkylsulphonyl, nitro or trifluoromethyl].

5

L^1 may particularly represent a $-R^6-R^7-$ linkage where R^6 represents a straight or branched C_{1-6} alkylene chain, especially a straight or branched C_{1-4} alkylene chain, and R^7 represents $-C(=Z^3)-NR^5-$, preferably $-C(=O)-NR^5-$, especially where R^5 is hydrogen or lower alkyl (e.g. methyl).

10

R^2 may particularly represent hydrogen.

R^2 may also particularly represent lower alkyl (e.g. methyl).

15 R^2 may also particularly represent lower alkoxy (e.g. methoxy).

L^2 may particularly represent a straight or branched C_{1-4} alkylene chain, especially ethylene, substituted by $-N(R^8)-C(=O)-R^9$, $-N(R^8)-C(=O)-OR^9$, $-N(R^8)-SO_2-R^9$, or $-NY^3Y^4$. L^2 is preferably a group $\text{---}\underset{\text{R}^{11}}{\text{CH}}\text{---CH}_2\text{---}$, particularly $\text{---}\underset{\text{R}^{11}}{\text{CH}}\text{---CH}_2\text{---}$, where R^{11} is


20 $-N(R^8)-C(=O)-R^9$, $-N(R^8)-C(=O)-OR^9$, $-N(R^8)-SO_2-R^9$, or $-NY^3Y^4$.

Y may particularly represent carboxy.

25 It is to be understood that this invention covers all appropriate combinations of the particular and preferred groupings referred to herein.

30

A particular group of compounds of the invention are compounds of formula (Ia):-



- 5 in which R^1 , R^2 , R^5 , R^6 , L^2 , Y and Z^1 are as defined in any preceding claim, R^{12} is hydrogen, acyl, acylamino, alkoxy, alkoxy carbonyl, alkylendioxy, alkylsulphinyl, alkylsulphonyl, alkylthio, aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy, aryloxycarbonyl, arylsulphinyl, arylsulphonyl, arylthio, carboxy, cyano, halo, heteroaroyl, heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, hydroxy, nitro,
- 10 trifluoromethyl, Y^1Y^2N- , Y^1Y^2NCO- , $Y^1Y^2NSO_2-$, $Y^1Y^2N-C_{2-6}$ alkylene- $Z-$, alkylC(=O)- Y^1N- , alkylSO₂- Y^1N- or alkyl optionally substituted with aryl, heteroaryl, hydroxy, or Y^1Y^2N- , and X is O, and their prodrugs and pharmaceutically acceptable salts, and solvates (e.g. hydrates) of compounds of formula (Ia) and their prodrugs.
- 15 Compounds of formula (Ia) in which R^1 represents optionally substituted aryl, especially optionally substituted phenyl, are preferred. Preferred optional substituents include lower alkyl (e.g. methyl), lower alkyl (e.g. methoxy), halo (e.g. fluoro) and Y^1Y^2N- (e.g. dimethylamino). R^1 especially represents ortho-tolyl.
- 20 Compounds of formula (Ia) in which Z^1 represents NH are preferred.
- Compounds of formula (Ia) in which R^{12} represents hydrogen, C₁₋₄ alkyl or C₁₋₄ alkoxy are preferred.
- 25 Compounds of formula (Ia) in which R^6 represents a straight or branched C₁₋₆alkylene chain, especially a straight or branched C₁₋₄alkylene chain, more especially methylene, are preferred.
- Compounds of formula (Ia) in which R^5 represents hydrogen are preferred.

Compounds of formula (Ia) in which R^2 represents hydrogen are preferred.

Compounds of formula (Ia) in which L^2 represents a straight C_{1-4} alkylene chain, especially ethylene, substituted by $-N(R^8)-C(=O)-R^9$, $-N(R^8)-C(=O)-OR^9$, $-N(R^8)-SO_2-R^9$ or $-NY^3Y^4$ are


5 also preferred. Compounds of formula (Ia) in which L^2 is a $\text{---CH---CH}_2\text{---}$ linkage,
 R^{11}

particularly $\text{---CH---CH}_2\text{---}$, where R^{11} is $-N(R^8)-C(=O)-R^9$, $-N(R^8)-C(=O)-OR^9$,
 R^{11}

$-N(R^8)-SO_2-R^9$ or $-NY^3Y^4$ are especially preferred.

Compounds of formula (Ia) in which Y represents carboxy are preferred.

10




A preferred group of compounds of the invention are compounds of formula (Ia) in which:- R^1 is optionally substituted phenyl (especially ortho-tolyl); Z^1 is NH; X is O; R^6 is a straight

15 C_{1-4} alkylene chain (especially methylene); R^2 and R^5 and R^{12} are each hydrogen; L^2 is a

$\text{---CH---CH}_2\text{---}$ linkage, particularly $\text{---CH---CH}_2\text{---}$, where R^{11} is $-N(R^8)-C(=O)-R^9$,
 R^{11}

$-N(R^8)-C(=O)-OR^9$, $-N(R^8)-SO_2-R^9$ or $-NY^3Y^4$; Y is carboxy; and the group

















N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates)

20 of such compounds and their N-oxides and prodrugs.

Particular compounds of the invention are selected from the compounds formed by joining the acyl carbon atom (C*) of one of the fragments (A1 to A32) shown in Table 1 to the nitrogen atom (N*) of one of the fragments (B1 or B2) shown in Table 2, and joining the carbon atom (C*) of the phenyl ring in one of the fragments (B1 or B2) shown in Table 2 to the carbon atom (C*) of one of the acidic fragments (C1 to C30) depicted in Table 3.

TABLE 1

A1		A2	
A3		A4	
A5		A6	
A7		A8	
A9		A10	
A11		A12	
A13		A14	

A15		A16	
A17		A18	
A19		A20	
A21		A22	
A23		A24	
A25		A26	
A27		A28	
A29		A30	



A31		A32	
-----	---	-----	--

TABLE 2























B1		B2	
----	---	----	---

TABLE 3

C1		C2	
C3		C4	
C5		C6	
C7		C8	

C9		C10	
C11		C12	
C13		C14	
C15		C16	
C17		C18	
C19		C20	

C21	$ \begin{array}{c} \text{*CH-CH}_2\text{-CO}_2\text{H} \\ \\ \text{HN} \\ \\ \text{C=O} \\ \\ \text{C}_6\text{H}_4 \\ \\ \text{H}_2\text{C-N} \begin{array}{c} \diagup \diagdown \\ \text{CH}_2 \text{ CH}_2 \text{ O} \end{array} \end{array} $	C22	$ \begin{array}{c} \text{*CH}_2\text{-CH-CO}_2\text{H} \\ \\ \text{HN} \\ \\ \text{C=O} \\ \\ \text{H}_2\text{C-N} \begin{array}{c} \diagup \diagdown \\ \text{CH}_2 \text{ CH}_2 \text{ N-CH}_3 \end{array} \end{array} $
C23	$ \begin{array}{c} \text{*CH-CH}_2\text{-CO}_2\text{H} \\ \\ \text{Me-N} \\ \\ \text{C=O} \\ \\ \text{C}_6\text{H}_5 \end{array} $	C24	$ \begin{array}{c} \text{*CH-CH}_2\text{-CO}_2\text{H} \\ \\ \text{Me-N} \\ \\ \text{C=O} \\ \\ \text{C}_5\text{H}_3\text{NO} \\ \\ \text{H}_3\text{C} \end{array} $
C25	$ \begin{array}{c} \text{*CH-CH}_2\text{-CO}_2\text{H} \\ \\ \text{Me-N} \\ \\ \text{C=O} \\ \\ \text{CH}_3 \end{array} $	C26	$ \begin{array}{c} \text{*CH-CH}_2\text{-CO}_2\text{H} \\ \\ \text{Me-N} \\ \\ \text{C=O} \\ \\ \text{C}_5\text{H}_4\text{N} \end{array} $
C27	$ \begin{array}{c} \text{*CH-CH}_2\text{-CO}_2\text{H} \\ \\ \text{Me-N} \\ \\ \text{C=O} \\ \\ \text{C}_6\text{H}_{10}\text{O} \end{array} $	C28	$ \begin{array}{c} \text{*CH-CH}_2\text{-CO}_2\text{H} \\ \\ \text{Me-N} \\ \\ \text{C=O} \\ \\ \text{C}_4\text{H}_3\text{S} \end{array} $
C29	$ \begin{array}{c} \text{*CH}_2\text{-CH-CO}_2\text{H} \\ \\ \text{Me-N} \\ \\ \text{C=O} \\ \\ \text{H}_2\text{C-O} \\ \\ \text{H}_2\text{C-CH}_2\text{-OMe} \end{array} $	C30	$ \begin{array}{c} \text{*CH-CH}_2\text{-CO}_2\text{H} \\ \\ \text{Me-N} \\ \\ \text{C=O} \\ \\ \text{C}_6\text{H}_3\text{OMe}_2 \end{array} $

Particularly preferred examples of fragments "A", "B", and "C" are illustrated below:

A1-B1-C1;	A1-B1-C6;	A1-B1-C11;	A1-B1-C16;	A1-B1-C21;	A1-B1-C26;
A1-B1-C2;	A1-B1-C7;	A1-B1-C12;	A1-B1-C17;	A1-B1-C22;	A1-B1-C27;
A1-B1-C3;	A1-B1-C8;	A1-B1-C13;	A1-B1-C18;	A1-B1-C23;	A1-B1-C28;
A1-B1-C4;	A1-B1-C9;	A1-B1-C14;	A1-B1-C19;	A1-B1-C24;	A1-B1-C29;
A1-B1-C5;	A1-B1-C10;	A1-B1-C15;	A1-B1-C20;	A1-B1-C25;	A1-B1-C30;

A2-B1-C1;	A3-B1-C6;	A4-B1-C11;	A5-B1-C16;	A6-B1-C21;	A7-B1-C26;
A2-B1-C2;	A3-B1-C7;	A4-B1-C12;	A5-B1-C17;	A6-B1-C22;	A7-B1-C27;
A2-B1-C3;	A3-B1-C8;	A4-B1-C13;	A5-B1-C18;	A6-B1-C23;	A7-B1-C28;
A2-B1-C4;	A3-B1-C9;	A4-B1-C14;	A5-B1-C19;	A6-B1-C24;	A7-B1-C29;
A2-B1-C5;	A3-B1-C10;	A4-B1-C15;	A5-B1-C20;	A6-B1-C25;	A7-B1-C30;
A2-B1-C6;	A3-B1-C11;	A4-B1-C16;	A5-B1-C21;	A6-B1-C26;	A8-B1-C1;
A2-B1-C7;	A3-B1-C12;	A4-B1-C17;	A5-B1-C22;	A6-B1-C27;	A8-B1-C2;
A2-B1-C8;	A3-B1-C13;	A4-B1-C18;	A5-B1-C23;	A6-B1-C28;	A8-B1-C3;
A2-B1-C9;	A3-B1-C14;	A4-B1-C19;	A5-B1-C24;	A6-B1-C29;	A8-B1-C4;
A2-B1-C10;	A3-B1-C15;	A4-B1-C20;	A5-B1-C25;	A6-B1-C30;	A8-B1-C5;
A2-B1-C11;	A3-B1-C16;	A4-B1-C21;	A5-B1-C26;	A7-B1-C1;	A8-B1-C6;
A2-B1-C12;	A3-B1-C17;	A4-B1-C22;	A5-B1-C27;	A7-B1-C2;	A8-B1-C7;
A2-B1-C13;	A3-B1-C18;	A4-B1-C23;	A5-B1-C28;	A7-B1-C3;	A8-B1-C8;
A2-B1-C14;	A3-B1-C19;	A4-B1-C24;	A5-B1-C29;	A7-B1-C4;	A8-B1-C9;
A2-B1-C15;	A3-B1-C20;	A4-B1-C25;	A5-B1-C30;	A7-B1-C5;	A8-B1-C10;
A2-B1-C16;	A3-B1-C21;	A4-B1-C26;	A6-B1-C1;	A7-B1-C6;	A8-B1-C11;
A2-B1-C17;	A3-B1-C22;	A4-B1-C27;	A6-B1-C2;	A7-B1-C7;	A8-B1-C12;
A2-B1-C18;	A3-B1-C23;	A4-B1-C28;	A6-B1-C3;	A7-B1-C8;	A8-B1-C13;
A2-B1-C19;	A3-B1-C24;	A4-B1-C29;	A6-B1-C4;	A7-B1-C9;	A8-B1-C14;
A2-B1-C20;	A3-B1-C25;	A4-B1-C30;	A6-B1-C5;	A7-B1-C10;	A8-B1-C15;
A2-B1-C21;	A3-B1-C26;	A5-B1-C1;	A6-B1-C6;	A7-B1-C11;	A8-B1-C16;
A2-B1-C22;	A3-B1-C27;	A5-B1-C2;	A6-B1-C7;	A7-B1-C12;	A8-B1-C17;
A2-B1-C23;	A3-B1-C28;	A5-B1-C3;	A6-B1-C8;	A7-B1-C13;	A8-B1-C18;
A2-B1-C24;	A3-B1-C29;	A5-B1-C4;	A6-B1-C9;	A7-B1-C14;	A8-B1-C19;
A2-B1-C25;	A3-B1-C30;	A5-B1-C5;	A6-B1-C10;	A7-B1-C15;	A8-B1-C20;
A2-B1-C26;	A4-B1-C1;	A5-B1-C6;	A6-B1-C11;	A7-B1-C16;	A8-B1-C21;
A2-B1-C27;	A4-B1-C2;	A5-B1-C7;	A6-B1-C12;	A7-B1-C17;	A8-B1-C22;
A2-B1-C28;	A4-B1-C3;	A5-B1-C8;	A6-B1-C13;	A7-B1-C18;	A8-B1-C23;
A2-B1-C29;	A4-B1-C4;	A5-B1-C9;	A6-B1-C14;	A7-B1-C19;	A8-B1-C24;
A2-B1-C30;	A4-B1-C5;	A5-B1-C10;	A6-B1-C15;	A7-B1-C20;	A8-B1-C25;
A3-B1-C1;	A4-B1-C6;	A5-B1-C11;	A6-B1-C16;	A7-B1-C21;	A8-B1-C26;
A3-B1-C2;	A4-B1-C7;	A5-B1-C12;	A6-B1-C17;	A7-B1-C22;	A8-B1-C27;
A3-B1-C3;	A4-B1-C8;	A5-B1-C13;	A6-B1-C18;	A7-B1-C23;	A8-B1-C28;
A3-B1-C4;	A4-B1-C9;	A5-B1-C14;	A6-B1-C19;	A7-B1-C24;	A8-B1-C29;
A3-B1-C5;	A4-B1-C10;	A5-B1-C15;	A6-B1-C20;	A7-B1-C25;	A8-B1-C30;

A9-B1-C1;	A10-B1-C6;	A11-B1-C11;	A12-B1-C16;	A13-B1-C21;	A14-B1-C26;
A9-B1-C2;	A10-B1-C7;	A11-B1-C12;	A12-B1-C17;	A13-B1-C22;	A14-B1-C27;
A9-B1-C3;	A10-B1-C8;	A11-B1-C13;	A12-B1-C18;	A13-B1-C23;	A14-B1-C28;
A9-B1-C4;	A10-B1-C9;	A11-B1-C14;	A12-B1-C19;	A13-B1-C24;	A14-B1-C29;
A9-B1-C5;	A10-B1-C10;	A11-B1-C15;	A12-B1-C20;	A13-B1-C25;	A14-B1-C30;
A9-B1-C6;	A10-B1-C11;	A11-B1-C16;	A12-B1-C21;	A13-B1-C26;	A15-B1-C1;
A9-B1-C7;	A10-B1-C12;	A11-B1-C17;	A12-B1-C22;	A13-B1-C27;	A15-B1-C2;
A9-B1-C8;	A10-B1-C13;	A11-B1-C18;	A12-B1-C23;	A13-B1-C28;	A15-B1-C3;
A9-B1-C9;	A10-B1-C14;	A11-B1-C19;	A12-B1-C24;	A13-B1-C29;	A15-B1-C4;
A9-B1-C10;	A10-B1-C15;	A11-B1-C20;	A12-B1-C25;	A13-B1-C30;	A15-B1-C5;
A9-B1-C11;	A10-B1-C16;	A11-B1-C21;	A12-B1-C26;	A14-B1-C1;	A15-B1-C6;
A9-B1-C12;	A10-B1-C17;	A11-B1-C22;	A12-B1-C27;	A14-B1-C2;	A15-B1-C7;
A9-B1-C13;	A10-B1-C18;	A11-B1-C23;	A12-B1-C28;	A14-B1-C3;	A15-B1-C8;
A9-B1-C14;	A10-B1-C19;	A11-B1-C24;	A12-B1-C29;	A14-B1-C4;	A15-B1-C9;
A9-B1-C15;	A10-B1-C20;	A11-B1-C25;	A12-B1-C30;	A14-B1-C5;	A15-B1-C10;
A9-B1-C16;	A10-B1-C21;	A11-B1-C26;	A13-B1-C1;	A14-B1-C6;	A15-B1-C11;
A9-B1-C17;	A10-B1-C22;	A11-B1-C27;	A13-B1-C2;	A14-B1-C7;	A15-B1-C12;
A9-B1-C18;	A10-B1-C23;	A11-B1-C28;	A13-B1-C3;	A14-B1-C8;	A15-B1-C13;
A9-B1-C19;	A10-B1-C24;	A11-B1-C29;	A13-B1-C4;	A14-B1-C9;	A15-B1-C14;
A9-B1-C20;	A10-B1-C25;	A11-B1-C30;	A13-B1-C5;	A14-B1-C10;	A15-B1-C15;
A9-B1-C21;	A10-B1-C26;	A12-B1-C1;	A13-B1-C6;	A14-B1-C11;	A15-B1-C16;
A9-B1-C22;	A10-B1-C27;	A12-B1-C2;	A13-B1-C7;	A14-B1-C12;	A15-B1-C17;
A9-B1-C23;	A10-B1-C28;	A12-B1-C3;	A13-B1-C8;	A14-B1-C13;	A15-B1-C18;
A9-B1-C24;	A10-B1-C29;	A12-B1-C4;	A13-B1-C9;	A14-B1-C14;	A15-B1-C19;
A9-B1-C25;	A10-B1-C30;	A12-B1-C5;	A13-B1-C10;	A14-B1-C15;	A15-B1-C20;
A9-B1-C26;	A11-B1-C1;	A12-B1-C6;	A13-B1-C11;	A14-B1-C16;	A15-B1-C21;
A9-B1-C27;	A11-B1-C2;	A12-B1-C7;	A13-B1-C12;	A14-B1-C17;	A15-B1-C22;
A9-B1-C28;	A11-B1-C3;	A12-B1-C8;	A13-B1-C13;	A14-B1-C18;	A15-B1-C23;
A9-B1-C29;	A11-B1-C4;	A12-B1-C9;	A13-B1-C14;	A14-B1-C19;	A15-B1-C24;
A9-B1-C30;	A11-B1-C5;	A12-B1-C10;	A13-B1-C15;	A14-B1-C20;	A15-B1-C25;
A10-B1-C1;	A11-B1-C6;	A12-B1-C11;	A13-B1-C16;	A14-B1-C21;	A15-B1-C26;
A10-B1-C2;	A11-B1-C7;	A12-B1-C12;	A13-B1-C17;	A14-B1-C22;	A15-B1-C27;
A10-B1-C3;	A11-B1-C8;	A12-B1-C13;	A13-B1-C18;	A14-B1-C23;	A15-B1-C28;
A10-B1-C4;	A11-B1-C9;	A12-B1-C14;	A13-B1-C19;	A14-B1-C24;	A15-B1-C29;
A10-B1-C5;	A11-B1-C10;	A12-B1-C15;	A13-B1-C20;	A14-B1-C25;	A15-B1-C30;

A16-B1-C1;	A17-B1-C6;	A18-B1-C11;	A19-B1-C16;	A20-B1-C21;	A21-B1-C26;
A16-B1-C2;	A17-B1-C7;	A18-B1-C12;	A19-B1-C17;	A20-B1-C22;	A21-B1-C27;
A16-B1-C3;	A17-B1-C8;	A18-B1-C13;	A19-B1-C18;	A20-B1-C23;	A21-B1-C28;
A16-B1-C4;	A17-B1-C9;	A18-B1-C14;	A19-B1-C19;	A20-B1-C24;	A21-B1-C29;
A16-B1-C5;	A17-B1-C10;	A18-B1-C15;	A19-B1-C20;	A20-B1-C25;	A21-B1-C30;
A16-B1-C6;	A17-B1-C11;	A18-B1-C16;	A19-B1-C21;	A20-B1-C26;	A22-B1-C1;
A16-B1-C7;	A17-B1-C12;	A18-B1-C17;	A19-B1-C22;	A20-B1-C27;	A22-B1-C2;
A16-B1-C8;	A17-B1-C13;	A18-B1-C18;	A19-B1-C23;	A20-B1-C28;	A22-B1-C3;
A16-B1-C9;	A17-B1-C14;	A18-B1-C19;	A19-B1-C24;	A20-B1-C29;	A22-B1-C4;
A16-B1-C10;	A17-B1-C15;	A18-B1-C20;	A19-B1-C25;	A20-B1-C30;	A22-B1-C5;
A16-B1-C11;	A17-B1-C16;	A18-B1-C21;	A19-B1-C26;	A21-B1-C1;	A22-B1-C6;
A16-B1-C12;	A17-B1-C17;	A18-B1-C22;	A19-B1-C27;	A21-B1-C2;	A22-B1-C7;
A16-B1-C13;	A17-B1-C18;	A18-B1-C23;	A19-B1-C28;	A21-B1-C3;	A22-B1-C8;
A16-B1-C14;	A17-B1-C19;	A18-B1-C24;	A19-B1-C29;	A21-B1-C4;	A22-B1-C9;
A16-B1-C15;	A17-B1-C20;	A18-B1-C25;	A19-B1-C30;	A21-B1-C5;	A22-B1-C10;
A16-B1-C16;	A17-B1-C21;	A18-B1-C26;	A20-B1-C1;	A21-B1-C6;	A22-B1-C11;
A16-B1-C17;	A17-B1-C22;	A18-B1-C27;	A20-B1-C2;	A21-B1-C7;	A22-B1-C12;
A16-B1-C18;	A17-B1-C23;	A18-B1-C28;	A20-B1-C3;	A21-B1-C8;	A22-B1-C13;
A16-B1-C19;	A17-B1-C24;	A18-B1-C29;	A20-B1-C4;	A21-B1-C9;	A22-B1-C14;
A16-B1-C20;	A17-B1-C25;	A18-B1-C30;	A20-B1-C5;	A21-B1-C10;	A22-B1-C15;
A16-B1-C21;	A17-B1-C26;	A19-B1-C1;	A20-B1-C6;	A21-B1-C11;	A22-B1-C16;
A16-B1-C22;	A17-B1-C27;	A19-B1-C2;	A20-B1-C7;	A21-B1-C12;	A22-B1-C17;
A16-B1-C23;	A17-B1-C28;	A19-B1-C3;	A20-B1-C8;	A21-B1-C13;	A22-B1-C18;
A16-B1-C24;	A17-B1-C29;	A19-B1-C4;	A20-B1-C9;	A21-B1-C14;	A22-B1-C19;
A16-B1-C25;	A17-B1-C30;	A19-B1-C5;	A20-B1-C10;	A21-B1-C15;	A22-B1-C20;
A16-B1-C26;	A18-B1-C1;	A19-B1-C6;	A20-B1-C11;	A21-B1-C16;	A22-B1-C21;
A16-B1-C27;	A18-B1-C2;	A19-B1-C7;	A20-B1-C12;	A21-B1-C17;	A22-B1-C22;
A16-B1-C28;	A18-B1-C3;	A19-B1-C8;	A20-B1-C13;	A21-B1-C18;	A22-B1-C23;
A16-B1-C29;	A18-B1-C4;	A19-B1-C9;	A20-B1-C14;	A21-B1-C19;	A22-B1-C24;
A16-B1-C30;	A18-B1-C5;	A19-B1-C10;	A20-B1-C15;	A21-B1-C20;	A22-B1-C25;
A17-B1-C1;	A18-B1-C6;	A19-B1-C11;	A20-B1-C16;	A21-B1-C21;	A22-B1-C26;
A17-B1-C2;	A18-B1-C7;	A19-B1-C12;	A20-B1-C17;	A21-B1-C22;	A22-B1-C27;
A17-B1-C3;	A18-B1-C8;	A19-B1-C13;	A20-B1-C18;	A21-B1-C23;	A22-B1-C28;
A17-B1-C4;	A18-B1-C9;	A19-B1-C14;	A20-B1-C19;	A21-B1-C24;	A22-B1-C29;
A17-B1-C5;	A18-B1-C10;	A19-B1-C15;	A20-B1-C20;	A21-B1-C25;	A22-B1-C30;

A23-B1-C1;	A24-B1-C6;	A25-B1-C11;	A26-B1-C16;	A27-B1-C21;	A28-B1-C26;
A23-B1-C2;	A24-B1-C7;	A25-B1-C12;	A26-B1-C17;	A27-B1-C22;	A28-B1-C27;
A23-B1-C3;	A24-B1-C8;	A25-B1-C13;	A26-B1-C18;	A27-B1-C23;	A28-B1-C28;
A23-B1-C4;	A24-B1-C9;	A25-B1-C14;	A26-B1-C19;	A27-B1-C24;	A28-B1-C29;
A23-B1-C5;	A24-B1-C10;	A25-B1-C15;	A26-B1-C20;	A27-B1-C25;	A28-B1-C30;
A23-B1-C6;	A24-B1-C11;	A25-B1-C16;	A26-B1-C21;	A27-B1-C26;	A29-B1-C1;
A23-B1-C7;	A24-B1-C12;	A25-B1-C17;	A26-B1-C22;	A27-B1-C27;	A29-B1-C2;
A23-B1-C8;	A24-B1-C13;	A25-B1-C18;	A26-B1-C23;	A27-B1-C28;	A29-B1-C3;
A23-B1-C9;	A24-B1-C14;	A25-B1-C19;	A26-B1-C24;	A27-B1-C29;	A29-B1-C4;
A23-B1-C10;	A24-B1-C15;	A25-B1-C20;	A26-B1-C25;	A27-B1-C30;	A29-B1-C5;
A23-B1-C11;	A24-B1-C16;	A25-B1-C21;	A26-B1-C26;	A28-B1-C1;	A29-B1-C6;
A23-B1-C12;	A24-B1-C17;	A25-B1-C22;	A26-B1-C27;	A28-B1-C2;	A29-B1-C7;
A23-B1-C13;	A24-B1-C18;	A25-B1-C23;	A26-B1-C28;	A28-B1-C3;	A29-B1-C8;
A23-B1-C14;	A24-B1-C19;	A25-B1-C24;	A26-B1-C29;	A28-B1-C4;	A29-B1-C9;
A23-B1-C15;	A24-B1-C20;	A25-B1-C25;	A26-B1-C30;	A28-B1-C5;	A29-B1-C10;
A23-B1-C16;	A24-B1-C21;	A25-B1-C26;	A27-B1-C1;	A28-B1-C6;	A29-B1-C11;
A23-B1-C17;	A24-B1-C22;	A25-B1-C27;	A27-B1-C2;	A28-B1-C7;	A29-B1-C12;
A23-B1-C18;	A24-B1-C23;	A25-B1-C28;	A27-B1-C3;	A28-B1-C8;	A29-B1-C13;
A23-B1-C19;	A24-B1-C24;	A25-B1-C29;	A27-B1-C4;	A28-B1-C9;	A29-B1-C14;
A23-B1-C20;	A24-B1-C25;	A25-B1-C30;	A27-B1-C5;	A28-B1-C10;	A29-B1-C15;
A23-B1-C21;	A24-B1-C26;	A26-B1-C1;	A27-B1-C6;	A28-B1-C11;	A29-B1-C16;
A23-B1-C22;	A24-B1-C27;	A26-B1-C2;	A27-B1-C7;	A28-B1-C12;	A29-B1-C17;
A23-B1-C23;	A24-B1-C28;	A26-B1-C3;	A27-B1-C8;	A28-B1-C13;	A29-B1-C18;
A23-B1-C24;	A24-B1-C29;	A26-B1-C4;	A27-B1-C9;	A28-B1-C14;	A29-B1-C19;
A23-B1-C25;	A24-B1-C30;	A26-B1-C5;	A27-B1-C10;	A28-B1-C15;	A29-B1-C20;
A23-B1-C26;	A25-B1-C1;	A26-B1-C6;	A27-B1-C11;	A28-B1-C16;	A29-B1-C21;
A23-B1-C27;	A25-B1-C2;	A26-B1-C7;	A27-B1-C12;	A28-B1-C17;	A29-B1-C22;
A23-B1-C28;	A25-B1-C3;	A26-B1-C8;	A27-B1-C13;	A28-B1-C18;	A29-B1-C23;
A23-B1-C29;	A25-B1-C4;	A26-B1-C9;	A27-B1-C14;	A28-B1-C19;	A29-B1-C24;
A23-B1-C30;	A25-B1-C5;	A26-B1-C10;	A27-B1-C15;	A28-B1-C20;	A29-B1-C25;
A24-B1-C1;	A25-B1-C6;	A26-B1-C11;	A27-B1-C16;	A28-B1-C21;	A29-B1-C26;
A24-B1-C2;	A25-B1-C7;	A26-B1-C12;	A27-B1-C17;	A28-B1-C22;	A29-B1-C27;
A24-B1-C3;	A25-B1-C8;	A26-B1-C13;	A27-B1-C18;	A28-B1-C23;	A29-B1-C28;
A24-B1-C4;	A25-B1-C9;	A26-B1-C14;	A27-B1-C19;	A28-B1-C24;	A29-B1-C29;
A24-B1-C5;	A25-B1-C10;	A26-B1-C15;	A27-B1-C20;	A28-B1-C25;	A29-B1-C30;

A30-B1-C1;	A31-B1-C6;	A32-B1-C11;	A1-B2-C16;	A2-B2-C21;	A3-B2-C26;
A30-B1-C2;	A31-B1-C7;	A32-B1-C12;	A1-B2-C17;	A2-B2-C22;	A3-B2-C27;
A30-B1-C3;	A31-B1-C8;	A32-B1-C13;	A1-B2-C18;	A2-B2-C23;	A3-B2-C28;
A30-B1-C4;	A31-B1-C9;	A32-B1-C14;	A1-B2-C19;	A2-B2-C24;	A3-B2-C29;
A30-B1-C5;	A31-B1-C10;	A32-B1-C15;	A1-B2-C20;	A2-B2-C25;	A3-B2-C30;
A30-B1-C6;	A31-B1-C11;	A32-B1-C16;	A1-B2-C21;	A2-B2-C26;	A4-B2-C1;
A30-B1-C7;	A31-B1-C12;	A32-B1-C17;	A1-B2-C22;	A2-B2-C27;	A4-B2-C2;
A30-B1-C8;	A31-B1-C13;	A32-B1-C18;	A1-B2-C23;	A2-B2-C28;	A4-B2-C3;
A30-B1-C9;	A31-B1-C14;	A32-B1-C19;	A1-B2-C24;	A2-B2-C29;	A4-B2-C4;
A30-B1-C10;	A31-B1-C15;	A32-B1-C20;	A1-B2-C25;	A2-B2-C30;	A4-B2-C5;
A30-B1-C11;	A31-B1-C16;	A32-B1-C21;	A1-B2-C26;	A3-B2-C1;	A4-B2-C6;
A30-B1-C12;	A31-B1-C17;	A32-B1-C22;	A1-B2-C27;	A3-B2-C2;	A4-B2-C7;
A30-B1-C13;	A31-B1-C18;	A32-B1-C23;	A1-B2-C28;	A3-B2-C3;	A4-B2-C8;
A30-B1-C14;	A31-B1-C19;	A32-B1-C24;	A1-B2-C29;	A3-B2-C4;	A4-B2-C9;
A30-B1-C15;	A31-B1-C20;	A32-B1-C25;	A1-B2-C30;	A3-B2-C5;	A4-B2-C10;
A30-B1-C16;	A31-B1-C21;	A32-B1-C26;	A2-B2-C1;	A3-B2-C6;	A4-B2-C11;
A30-B1-C17;	A31-B1-C22;	A32-B1-C27;	A2-B2-C2;	A3-B2-C7;	A4-B2-C12;
A30-B1-C18;	A31-B1-C23;	A32-B1-C28;	A2-B2-C3;	A3-B2-C8;	A4-B2-C13;
A30-B1-C19;	A31-B1-C24;	A32-B1-C29;	A2-B2-C4;	A3-B2-C9;	A4-B2-C14;
A30-B1-C20;	A31-B1-C25;	A32-B1-C30;	A2-B2-C5;	A3-B2-C10;	A4-B2-C15;
A30-B1-C21;	A31-B1-C26;	A1-B2-C1;	A2-B2-C6;	A3-B2-C11;	A4-B2-C16;
A30-B1-C22;	A31-B1-C27;	A1-B2-C2;	A2-B2-C7;	A3-B2-C12;	A4-B2-C17;
A30-B1-C23;	A31-B1-C28;	A1-B2-C3;	A2-B2-C8;	A3-B2-C13;	A4-B2-C18;
A30-B1-C24;	A31-B1-C29;	A1-B2-C4;	A2-B2-C9;	A3-B2-C14;	A4-B2-C19;
A30-B1-C25;	A31-B1-C30;	A1-B2-C5;	A2-B2-C10;	A3-B2-C15;	A4-B2-C20;
A30-B1-C26;	A32-B1-C1;	A1-B2-C6;	A2-B2-C11;	A3-B2-C16;	A4-B2-C21;
A30-B1-C27;	A32-B1-C2;	A1-B2-C7;	A2-B2-C12;	A3-B2-C17;	A4-B2-C22;
A30-B1-C28;	A32-B1-C3;	A1-B2-C8;	A2-B2-C13;	A3-B2-C18;	A4-B2-C23;
A30-B1-C29;	A32-B1-C4;	A1-B2-C9;	A2-B2-C14;	A3-B2-C19;	A4-B2-C24;
A30-B1-C30;	A32-B1-C5;	A1-B2-C10;	A2-B2-C15;	A3-B2-C20;	A4-B2-C25;
A31-B1-C1;	A32-B1-C6;	A1-B2-C11;	A2-B2-C16;	A3-B2-C21;	A4-B2-C26;
A31-B1-C2;	A32-B1-C7;	A1-B2-C12;	A2-B2-C17;	A3-B2-C22;	A4-B2-C27;
A31-B1-C3;	A32-B1-C8;	A1-B2-C13;	A2-B2-C18;	A3-B2-C23;	A4-B2-C28;
A31-B1-C4;	A32-B1-C9;	A1-B2-C14;	A2-B2-C19;	A3-B2-C24;	A4-B2-C29;
A31-B1-C5;	A32-B1-C10;	A1-B2-C15;	A2-B2-C20;	A3-B2-C25;	A4-B2-C30;

A5-B2-C1;	A6-B2-C6;	A7-B2-C11;	A8-B2-C16;	A9-B2-C21;	A10-B2-C26;
A5-B2-C2;	A6-B2-C7;	A7-B2-C12;	A8-B2-C17;	A9-B2-C22;	A10-B2-C27;
A5-B2-C3;	A6-B2-C8;	A7-B2-C13;	A8-B2-C18;	A9-B2-C23;	A10-B2-C28;
A5-B2-C4;	A6-B2-C9;	A7-B2-C14;	A8-B2-C19;	A9-B2-C24;	A10-B2-C29;
A5-B2-C5;	A6-B2-C10;	A7-B2-C15;	A8-B2-C20;	A9-B2-C25;	A10-B2-C30;
A5-B2-C6;	A6-B2-C11;	A7-B2-C16;	A8-B2-C21;	A9-B2-C26;	A11-B2-C1;
A5-B2-C7;	A6-B2-C12;	A7-B2-C17;	A8-B2-C22;	A9-B2-C27;	A11-B2-C2;
A5-B2-C8;	A6-B2-C13;	A7-B2-C18;	A8-B2-C23;	A9-B2-C28;	A11-B2-C3;
A5-B2-C9;	A6-B2-C14;	A7-B2-C19;	A8-B2-C24;	A9-B2-C29;	A11-B2-C4;
A5-B2-C10;	A6-B2-C15;	A7-B2-C20;	A8-B2-C25;	A9-B2-C30;	A11-B2-C5;
A5-B2-C11;	A6-B2-C16;	A7-B2-C21;	A8-B2-C26;	A10-B2-C1;	A11-B2-C6;
A5-B2-C12;	A6-B2-C17;	A7-B2-C22;	A8-B2-C27;	A10-B2-C2;	A11-B2-C7;
A5-B2-C13;	A6-B2-C18;	A7-B2-C23;	A8-B2-C28;	A10-B2-C3;	A11-B2-C8;
A5-B2-C14;	A6-B2-C19;	A7-B2-C24;	A8-B2-C29;	A10-B2-C4;	A11-B2-C9;
A5-B2-C15;	A6-B2-C20;	A7-B2-C25;	A8-B2-C30;	A10-B2-C5;	A11-B2-C10;
A5-B2-C16;	A6-B2-C21;	A7-B2-C26;	A9-B2-C1;	A10-B2-C6;	A11-B2-C11;
A5-B2-C17;	A6-B2-C22;	A7-B2-C27;	A9-B2-C2;	A10-B2-C7;	A11-B2-C12;
A5-B2-C18;	A6-B2-C23;	A7-B2-C28;	A9-B2-C3;	A10-B2-C8;	A11-B2-C13;
A5-B2-C19;	A6-B2-C24;	A7-B2-C29;	A9-B2-C4;	A10-B2-C9;	A11-B2-C14;
A5-B2-C20;	A6-B2-C25;	A7-B2-C30;	A9-B2-C5;	A10-B2-C10;	A11-B2-C15;
A5-B2-C21;	A6-B2-C26;	A8-B2-C1;	A9-B2-C6;	A10-B2-C11;	A11-B2-C16;
A5-B2-C22;	A6-B2-C27;	A8-B2-C2;	A9-B2-C7;	A10-B2-C12;	A11-B2-C17;
A5-B2-C23;	A6-B2-C28;	A8-B2-C3;	A9-B2-C8;	A10-B2-C13;	A11-B2-C18;
A5-B2-C24;	A6-B2-C29;	A8-B2-C4;	A9-B2-C9;	A10-B2-C14;	A11-B2-C19;
A5-B2-C25;	A6-B2-C30;	A8-B2-C5;	A9-B2-C10;	A10-B2-C15;	A11-B2-C20;
A5-B2-C26;	A7-B2-C1;	A8-B2-C6;	A9-B2-C11;	A10-B2-C16;	A11-B2-C21;
A5-B2-C27;	A7-B2-C2;	A8-B2-C7;	A9-B2-C12;	A10-B2-C17;	A11-B2-C22;
A5-B2-C28;	A7-B2-C3;	A8-B2-C8;	A9-B2-C13;	A10-B2-C18;	A11-B2-C23;
A5-B2-C29;	A7-B2-C4;	A8-B2-C9;	A9-B2-C14;	A10-B2-C19;	A11-B2-C24;
A5-B2-C30;	A7-B2-C5;	A8-B2-C10;	A9-B2-C15;	A10-B2-C20;	A11-B2-C25;
A6-B2-C1;	A7-B2-C6;	A8-B2-C11;	A9-B2-C16;	A10-B2-C21;	A11-B2-C26;
A6-B2-C2;	A7-B2-C7;	A8-B2-C12;	A9-B2-C17;	A10-B2-C22;	A11-B2-C27;
A6-B2-C3;	A7-B2-C8;	A8-B2-C13;	A9-B2-C18;	A10-B2-C23;	A11-B2-C28;
A6-B2-C4;	A7-B2-C9;	A8-B2-C14;	A9-B2-C19;	A10-B2-C24;	A11-B2-C29;
A6-B2-C5;	A7-B2-C10;	A8-B2-C15;	A9-B2-C20;	A10-B2-C25;	A11-B2-C30;


A12-B2-C1;	A13-B2-C6;	A14-B2-C11;	A15-B2-C16;	A16-B2-C21;	A17-B2-C26;
A12-B2-C2;	A13-B2-C7;	A14-B2-C12;	A15-B2-C17;	A16-B2-C22;	A17-B2-C27;
A12-B2-C3;	A13-B2-C8;	A14-B2-C13;	A15-B2-C18;	A16-B2-C23;	A17-B2-C28;
A12-B2-C4;	A13-B2-C9;	A14-B2-C14;	A15-B2-C19;	A16-B2-C24;	A17-B2-C29;
A12-B2-C5;	A13-B2-C10;	A14-B2-C15;	A15-B2-C20;	A16-B2-C25;	A17-B2-C30;
A12-B2-C6;	A13-B2-C11;	A14-B2-C16;	A15-B2-C21;	A16-B2-C26;	A18-B2-C1;
A12-B2-C7;	A13-B2-C12;	A14-B2-C17;	A15-B2-C22;	A16-B2-C27;	A18-B2-C2;
A12-B2-C8;	A13-B2-C13;	A14-B2-C18;	A15-B2-C23;	A16-B2-C28;	A18-B2-C3;
A12-B2-C9;	A13-B2-C14;	A14-B2-C19;	A15-B2-C24;	A16-B2-C29;	A18-B2-C4;
A12-B2-C10;	A13-B2-C15;	A14-B2-C20;	A15-B2-C25;	A16-B2-C30;	A18-B2-C5;
A12-B2-C11;	A13-B2-C16;	A14-B2-C21;	A15-B2-C26;	A17-B2-C1;	A18-B2-C6;
A12-B2-C12;	A13-B2-C17;	A14-B2-C22;	A15-B2-C27;	A17-B2-C2;	A18-B2-C7;
A12-B2-C13;	A13-B2-C18;	A14-B2-C23;	A15-B2-C28;	A17-B2-C3;	A18-B2-C8;
A12-B2-C14;	A13-B2-C19;	A14-B2-C24;	A15-B2-C29;	A17-B2-C4;	A18-B2-C9;
A12-B2-C15;	A13-B2-C20;	A14-B2-C25;	A15-B2-C30;	A17-B2-C5;	A18-B2-C10;
A12-B2-C16;	A13-B2-C21;	A14-B2-C26;	A16-B2-C1;	A17-B2-C6;	A18-B2-C11;
A12-B2-C17;	A13-B2-C22;	A14-B2-C27;	A16-B2-C2;	A17-B2-C7;	A18-B2-C12;
A12-B2-C18;	A13-B2-C23;	A14-B2-C28;	A16-B2-C3;	A17-B2-C8;	A18-B2-C13;
A12-B2-C19;	A13-B2-C24;	A14-B2-C29;	A16-B2-C4;	A17-B2-C9;	A18-B2-C14;
A12-B2-C20;	A13-B2-C25;	A14-B2-C30;	A16-B2-C5;	A17-B2-C10;	A18-B2-C15;
A12-B2-C21;	A13-B2-C26;	A15-B2-C1;	A16-B2-C6;	A17-B2-C11;	A18-B2-C16;
A12-B2-C22;	A13-B2-C27;	A15-B2-C2;	A16-B2-C7;	A17-B2-C12;	A18-B2-C17;
A12-B2-C23;	A13-B2-C28;	A15-B2-C3;	A16-B2-C8;	A17-B2-C13;	A18-B2-C18;
A12-B2-C24;	A13-B2-C29;	A15-B2-C4;	A16-B2-C9;	A17-B2-C14;	A18-B2-C19;
A12-B2-C25;	A13-B2-C30;	A15-B2-C5;	A16-B2-C10;	A17-B2-C15;	A18-B2-C20;
A12-B2-C26;	A14-B2-C1;	A15-B2-C6;	A16-B2-C11;	A17-B2-C16;	A18-B2-C21;
A12-B2-C27;	A14-B2-C2;	A15-B2-C7;	A16-B2-C12;	A17-B2-C17;	A18-B2-C22;
A12-B2-C28;	A14-B2-C3;	A15-B2-C8;	A16-B2-C13;	A17-B2-C18;	A18-B2-C23;
A12-B2-C29;	A14-B2-C4;	A15-B2-C9;	A16-B2-C14;	A17-B2-C19;	A18-B2-C24;
A12-B2-C30;	A14-B2-C5;	A15-B2-C10;	A16-B2-C15;	A17-B2-C20;	A18-B2-C25;
A13-B2-C1;	A14-B2-C6;	A15-B2-C11;	A16-B2-C16;	A17-B2-C21;	A18-B2-C26;
A13-B2-C2;	A14-B2-C7;	A15-B2-C12;	A16-B2-C17;	A17-B2-C22;	A18-B2-C27;
A13-B2-C3;	A14-B2-C8;	A15-B2-C13;	A16-B2-C18;	A17-B2-C23;	A18-B2-C28;
A13-B2-C4;	A14-B2-C9;	A15-B2-C14;	A16-B2-C19;	A17-B2-C24;	A18-B2-C29;
A13-B2-C5;	A14-B2-C10;	A15-B2-C15;	A16-B2-C20;	A17-B2-C25;	A18-B2-C30;

A19-B2-C1;	A20-B2-C6;	A21-B2-C11;	A22-B2-C16;	A23-B2-C21;	A24-B2-C26;
A19-B2-C2;	A20-B2-C7;	A21-B2-C12;	A22-B2-C17;	A23-B2-C22;	A24-B2-C27;
A19-B2-C3;	A20-B2-C8;	A21-B2-C13;	A22-B2-C18;	A23-B2-C23;	A24-B2-C28;
A19-B2-C4;	A20-B2-C9;	A21-B2-C14;	A22-B2-C19;	A23-B2-C24;	A24-B2-C29;
A19-B2-C5;	A20-B2-C10;	A21-B2-C15;	A22-B2-C20;	A23-B2-C25;	A24-B2-C30;
A19-B2-C6;	A20-B2-C11;	A21-B2-C16;	A22-B2-C21;	A23-B2-C26;	A25-B2-C1;
A19-B2-C7;	A20-B2-C12;	A21-B2-C17;	A22-B2-C22;	A23-B2-C27;	A25-B2-C2;
A19-B2-C8;	A20-B2-C13;	A21-B2-C18;	A22-B2-C23;	A23-B2-C28;	A25-B2-C3;
A19-B2-C9;	A20-B2-C14;	A21-B2-C19;	A22-B2-C24;	A23-B2-C29;	A25-B2-C4;
A19-B2-C10;	A20-B2-C15;	A21-B2-C20;	A22-B2-C25;	A23-B2-C30;	A25-B2-C5;
A19-B2-C11;	A20-B2-C16;	A21-B2-C21;	A22-B2-C26;	A24-B2-C1;	A25-B2-C6;
A19-B2-C12;	A20-B2-C17;	A21-B2-C22;	A22-B2-C27;	A24-B2-C2;	A25-B2-C7;
A19-B2-C13;	A20-B2-C18;	A21-B2-C23;	A22-B2-C28;	A24-B2-C3;	A25-B2-C8;
A19-B2-C14;	A20-B2-C19;	A21-B2-C24;	A22-B2-C29;	A24-B2-C4;	A25-B2-C9;
A19-B2-C15;	A20-B2-C20;	A21-B2-C25;	A22-B2-C30;	A24-B2-C5;	A25-B2-C10;
A19-B2-C16;	A20-B2-C21;	A21-B2-C26;	A23-B2-C1;	A24-B2-C6;	A25-B2-C11;
A19-B2-C17;	A20-B2-C22;	A21-B2-C27;	A23-B2-C2;	A24-B2-C7;	A25-B2-C12;
A19-B2-C18;	A20-B2-C23;	A21-B2-C28;	A23-B2-C3;	A24-B2-C8;	A25-B2-C13;
A19-B2-C19;	A20-B2-C24;	A21-B2-C29;	A23-B2-C4;	A24-B2-C9;	A25-B2-C14;
A19-B2-C20;	A20-B2-C25;	A21-B2-C30;	A23-B2-C5;	A24-B2-C10;	A25-B2-C15;
A19-B2-C21;	A20-B2-C26;	A22-B2-C1;	A23-B2-C6;	A24-B2-C11;	A25-B2-C16;
A19-B2-C22;	A20-B2-C27;	A22-B2-C2;	A23-B2-C7;	A24-B2-C12;	A25-B2-C17;
A19-B2-C23;	A20-B2-C28;	A22-B2-C3;	A23-B2-C8;	A24-B2-C13;	A25-B2-C18;
A19-B2-C24;	A20-B2-C29;	A22-B2-C4;	A23-B2-C9;	A24-B2-C14;	A25-B2-C19;
A19-B2-C25;	A20-B2-C30;	A22-B2-C5;	A23-B2-C10;	A24-B2-C15;	A25-B2-C20;
A19-B2-C26;	A21-B2-C1;	A22-B2-C6;	A23-B2-C11;	A24-B2-C16;	A25-B2-C21;
A19-B2-C27;	A21-B2-C2;	A22-B2-C7;	A23-B2-C12;	A24-B2-C17;	A25-B2-C22;
A19-B2-C28;	A21-B2-C3;	A22-B2-C8;	A23-B2-C13;	A24-B2-C18;	A25-B2-C23;
A19-B2-C29;	A21-B2-C4;	A22-B2-C9;	A23-B2-C14;	A24-B2-C19;	A25-B2-C24;
A19-B2-C30;	A21-B2-C5;	A22-B2-C10;	A23-B2-C15;	A24-B2-C20;	A25-B2-C25;
A20-B2-C1;	A21-B2-C6;	A22-B2-C11;	A23-B2-C16;	A24-B2-C21;	A25-B2-C26;
A20-B2-C2;	A21-B2-C7;	A22-B2-C12;	A23-B2-C17;	A24-B2-C22;	A25-B2-C27;
A20-B2-C3;	A21-B2-C8;	A22-B2-C13;	A23-B2-C18;	A24-B2-C23;	A25-B2-C28;
A20-B2-C4;	A21-B2-C9;	A22-B2-C14;	A23-B2-C19;	A24-B2-C24;	A25-B2-C29;
A20-B2-C5;	A21-B2-C10;	A22-B2-C15;	A23-B2-C20;	A24-B2-C25;	A25-B2-C30;

A26-B2-C1;	A27-B2-C6;	A28-B2-C11;	A29-B2-C16;	A30-B2-C21;	A31-B2-C26;
A26-B2-C2;	A27-B2-C7;	A28-B2-C12;	A29-B2-C17;	A30-B2-C22;	A31-B2-C27;
A26-B2-C3;	A27-B2-C8;	A28-B2-C13;	A29-B2-C18;	A30-B2-C23;	A31-B2-C28;
A26-B2-C4;	A27-B2-C9;	A28-B2-C14;	A29-B2-C19;	A30-B2-C24;	A31-B2-C29;
A26-B2-C5;	A27-B2-C10;	A28-B2-C15;	A29-B2-C20;	A30-B2-C25;	A31-B2-C30;
A26-B2-C6;	A27-B2-C11;	A28-B2-C16;	A29-B2-C21;	A30-B2-C26;	A32-B2-C1;
A26-B2-C7;	A27-B2-C12;	A28-B2-C17;	A29-B2-C22;	A30-B2-C27;	A32-B2-C2;
A26-B2-C8;	A27-B2-C13;	A28-B2-C18;	A29-B2-C23;	A30-B2-C28;	A32-B2-C3;
A26-B2-C9;	A27-B2-C14;	A28-B2-C19;	A29-B2-C24;	A30-B2-C29;	A32-B2-C4;
A26-B2-C10;	A27-B2-C15;	A28-B2-C20;	A29-B2-C25;	A30-B2-C30;	A32-B2-C5;
A26-B2-C11;	A27-B2-C16;	A28-B2-C21;	A29-B2-C26;	A31-B2-C1;	A32-B2-C6;
A26-B2-C12;	A27-B2-C17;	A28-B2-C22;	A29-B2-C27;	A31-B2-C2;	A32-B2-C7;
A26-B2-C13;	A27-B2-C18;	A28-B2-C23;	A29-B2-C28;	A31-B2-C3;	A32-B2-C8;
A26-B2-C14;	A27-B2-C19;	A28-B2-C24;	A29-B2-C29;	A31-B2-C4;	A32-B2-C9;
A26-B2-C15;	A27-B2-C20;	A28-B2-C25;	A29-B2-C30;	A31-B2-C5;	A32-B2-C10;
A26-B2-C16;	A27-B2-C21;	A28-B2-C26;	A30-B2-C1;	A31-B2-C6;	A32-B2-C11;
A26-B2-C17;	A27-B2-C22;	A28-B2-C27;	A30-B2-C2;	A31-B2-C7;	A32-B2-C12;
A26-B2-C18;	A27-B2-C23;	A28-B2-C28;	A30-B2-C3;	A31-B2-C8;	A32-B2-C13;
A26-B2-C19;	A27-B2-C24;	A28-B2-C29;	A30-B2-C4;	A31-B2-C9;	A32-B2-C14;
A26-B2-C20;	A27-B2-C25;	A28-B2-C30;	A30-B2-C5;	A31-B2-C10;	A32-B2-C15;
A26-B2-C21;	A27-B2-C26;	A29-B2-C1;	A30-B2-C6;	A31-B2-C11;	A32-B2-C16;
A26-B2-C22;	A27-B2-C27;	A29-B2-C2;	A30-B2-C7;	A31-B2-C12;	A32-B2-C17;
A26-B2-C23;	A27-B2-C28;	A29-B2-C3;	A30-B2-C8;	A31-B2-C13;	A32-B2-C18;
A26-B2-C24;	A27-B2-C29;	A29-B2-C4;	A30-B2-C9;	A31-B2-C14;	A32-B2-C19;
A26-B2-C25;	A27-B2-C30;	A29-B2-C5;	A30-B2-C10;	A31-B2-C15;	A32-B2-C20;
A26-B2-C26;	A28-B2-C1;	A29-B2-C6;	A30-B2-C11;	A31-B2-C16;	A32-B2-C21;
A26-B2-C27;	A28-B2-C2;	A29-B2-C7;	A30-B2-C12;	A31-B2-C17;	A32-B2-C22;
A26-B2-C28;	A28-B2-C3;	A29-B2-C8;	A30-B2-C13;	A31-B2-C18;	A32-B2-C23;
A26-B2-C29;	A28-B2-C4;	A29-B2-C9;	A30-B2-C14;	A31-B2-C19;	A32-B2-C24;
A26-B2-C30;	A28-B2-C5;	A29-B2-C10;	A30-B2-C15;	A31-B2-C20;	A32-B2-C25;
A27-B2-C1;	A28-B2-C6;	A29-B2-C11;	A30-B2-C16;	A31-B2-C21;	A32-B2-C26;
A27-B2-C2;	A28-B2-C7;	A29-B2-C12;	A30-B2-C17;	A31-B2-C22;	A32-B2-C27;
A27-B2-C3;	A28-B2-C8;	A29-B2-C13;	A30-B2-C18;	A31-B2-C23;	A32-B2-C28;
A27-B2-C4;	A28-B2-C9;	A29-B2-C14;	A30-B2-C19;	A31-B2-C24;	A32-B2-C29;
A27-B2-C5;	A28-B2-C10;	A29-B2-C15;	A30-B2-C20;	A31-B2-C25;	A32-B2-C30;

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

Thus, for example, in the above list the compound denoted as A1-B1-C2 is the product of the combination of group A1 in Table 1 and B1 in Table 2 and C2 in Table 3, namely



Preferred compounds of the invention are:

(R) 3-(benzoyl-amino)-3-(4-(((2-o-tolylamino-benzoxazol-6-yl)-acetyl)-amino)-phenyl)-propionic acid;

(R) 3-[(5-methyl-isoxazole-3-carbonyl)-amino]-3-{4-[2-(2-o-tolylamino-benzoxazol-6-yl)-acetylamino]-phenyl}-propionic acid;

3-(4-{2-[2-(2-methoxy-phenylamino)-benzoxazol-6-yl]-acetylamino}-phenyl)-3-[(5-methylisoxazole-3-carbonyl)-amino]-propionic acid;

3-(4-{2-[2-(2-chloro-phenylamino)-benzoxazol-6-yl]-acetylamino}-phenyl)-3-[(5-methylisoxazole-3-carbonyl)-amino]-propionic acid;

3-(4-{2-[2-(2-chloro-phenylamino)-benzoxazol-6-yl]-acetylamino}-phenyl)-3-[(pyridine-4-carbonyl)-amino]-propionic acid;

3-(4-{2-[2-(2-methyl-phenylamino)-benzoxazol-6-yl]-acetylamino}-phenyl)-3-[(thiophene-2-carbonyl)-amino]-propionic acid;

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates (e.g. hydrates) of such compounds and their N-oxides and prodrugs.

The compounds of the invention exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. The present invention thus provides, according to a further aspect, compounds of the invention and compositions containing compounds of the invention for use in therapy.

Compounds within the scope of the present invention block the interaction of the ligand VCAM-1 to its integrin receptor VLA-4 ($\alpha 4\beta 1$) according to tests described in the literature and described in vitro and in vivo procedures hereinafter, and which tests results are believed to correlate to pharmacological activity in humans and other mammals. Thus, in a further embodiment, the present invention provides compounds of the invention and compositions containing compounds of the invention for use in the treatment of a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of $\alpha 4\beta 1$ mediated cell adhesion. For example, compounds of the present invention are useful in the treatment of inflammatory diseases, for example joint inflammation, including arthritis, rheumatoid arthritis and other arthritic conditions such as rheumatoid spondylitis, gouty arthritis, traumatic arthritis, rubella arthritis, psoriatic arthritis and osteoarthritis. Additionally, the compounds are useful in the treatment of acute synovitis, autoimmune diabetes, autoimmune encephalomyelitis, colitis, atherosclerosis, peripheral vascular disease, cardiovascular disease, multiple sclerosis, asthma, psoriasis restenosis, myocarditis, inflammatory bowel disease and melanoma cell division in metastasis.

A special embodiment of the therapeutic methods of the present invention is the treating of asthma.

Another special embodiment of the therapeutic methods of the present invention is the treating of joint inflammation.

Another special embodiment of the therapeutic methods of the present invention is the treating of inflammatory bowel disease.

According to a further feature of the invention there is provided a method for the treatment of a human or animal patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of the interaction of the ligand VCAM-1 to its integrin receptor VLA-4 ($\alpha 4\beta 1$), for example conditions as hereinbefore described, which comprises the administration to the patient of an effective amount of compound of the invention or a composition containing a compound of the invention. "Effective amount" is meant to describe an amount of compound of the present invention effective in inhibiting the interaction of the ligand VCAM-1 to its integrin receptor VLA-4 ($\alpha 4\beta 1$), and thus producing the desired therapeutic effect.

References herein to treatment should be understood to include prophylactic therapy as well as treatment of established conditions.

5 The present invention also includes within its scope pharmaceutical compositions comprising at least one of the compounds of the invention in association with a pharmaceutically acceptable carrier or excipient.

Compounds of the invention may be administered by any suitable means. In practice
10 compounds of the present invention may generally be administered parenterally, topically, rectally, orally or by inhalation, especially by the oral route.

Compositions according to the invention may be prepared according to the customary methods, using one or more pharmaceutically acceptable adjuvants or excipients. The adjuvants
15 comprise, inter alia, diluents, sterile aqueous media and the various non-toxic organic solvents. The compositions may be presented in the form of tablets, pills, granules, powders, aqueous solutions or suspensions, injectable solutions, elixirs or syrups, and can contain one or more agents chosen from the group comprising sweeteners, flavourings, colourings, or stabilisers in order to obtain pharmaceutically acceptable preparations. The choice of vehicle and the content
20 of active substance in the vehicle are generally determined in accordance with the solubility and chemical properties of the active compound, the particular mode of administration and the provisions to be observed in pharmaceutical practice. For example, excipients such as lactose, sodium citrate, calcium carbonate, dicalcium phosphate and disintegrating agents such as starch, alginic acids and certain complex silicates combined with lubricants such as magnesium stearate,
25 sodium lauryl sulphate and talc may be used for preparing tablets. To prepare a capsule, it is advantageous to use lactose and high molecular weight polyethylene glycols. When aqueous suspensions are used they can contain emulsifying agents or agents which facilitate suspension. Diluents such as sucrose, ethanol, polyethylene glycol, propylene glycol, glycerol and chloroform or mixtures thereof may also be used.

30

For parenteral administration, emulsions, suspensions or solutions of the products according to the invention in vegetable oil, for example sesame oil, groundnut oil or olive oil, or aqueous-organic solutions such as water and propylene glycol, injectable organic esters such as ethyl oleate, as well as sterile aqueous solutions of the pharmaceutically acceptable salts, are
35 used. The solutions of the salts of the products according to the invention are especially useful for administration by intramuscular or subcutaneous injection. The aqueous solutions, also

comprising solutions of the salts in pure distilled water, may be used for intravenous administration with the proviso that their pH is suitably adjusted, that they are judiciously buffered and rendered isotonic with a sufficient quantity of glucose or sodium chloride and that they are sterilised by heating, irradiation or microfiltration.

5

For topical administration, gels (water or alcohol based), creams or ointments containing compounds of the invention may be used. Compounds of the invention may also be incorporated in a gel or matrix base for application in a patch, which would allow a controlled release of compound through the transdermal barrier.

10

For administration by inhalation compounds of the invention may be dissolved or suspended in a suitable carrier for use in a nebuliser or a suspension or solution aerosol, or may be absorbed or adsorbed onto a suitable solid carrier for use in a dry powder inhaler.

15

Solid compositions for rectal administration include suppositories formulated in accordance with known methods and containing at least one compound of the invention.

The percentage of active ingredient in the compositions of the invention may be varied, it being necessary that it should constitute a proportion such that a suitable dosage shall be obtained.

20

Obviously, several unit dosage forms may be administered at about the same time. The dose employed will be determined by the physician, and depends upon the desired therapeutic effect, the route of administration and the duration of the treatment, and the condition of the patient. In the adult, the doses are generally from about 0.001 to about 50, preferably about 0.001 to about 5, mg/kg body weight per day by inhalation, from about 0.01 to about 100, preferably 0.1 to 70, more especially 0.5 to 10, mg/kg body weight per day by oral administration, and from about 0.001 to about 10, preferably 0.01 to 1, mg/kg body weight per day by intravenous administration. In each particular case, the doses will be determined in accordance with the factors distinctive to the subject to be treated, such as age, weight, general state of health and other characteristics which can influence the efficacy of the medicinal product.

25

30

The compounds according to the invention may be administered as frequently as necessary in order to obtain the desired therapeutic effect. Some patients may respond rapidly to a higher or lower dose and may find much weaker maintenance doses adequate. For other patients, it may be necessary to have long-term treatments at the rate of 1 to 4 doses per day, in accordance with the physiological requirements of each particular patient. Generally, the active product may be

35

administered orally 1 to 4 times per day. Of course, for some patients, it will be necessary to prescribe not more than one or two doses per day.

Compounds of the invention may be prepared by the application or adaptation of known methods, by which is meant methods used heretofore or described in the literature, for example those described by R.C.Larock in *Comprehensive Organic Transformations*, VCH publishers, 1989.


In the reactions described hereinafter it may be necessary to protect reactive functional groups, for example hydroxy, amino, imino, thio or carboxy groups, where these are desired in the final product, to avoid their unwanted participation in the reactions. Conventional protecting groups may be used in accordance with standard practice, for examples see T.W. Greene and P. G. M. Wuts in "Protective Groups in Organic Chemistry" John Wiley and Sons, 1991.

Compounds of formula (I) wherein Het, R¹, R², L¹, L² and Z¹ are as hereinbefore defined, and Y is carboxy may be prepared by hydrolysis of esters of formula (I) wherein Het, R¹, R², L¹, L² and Z¹ are as hereinbefore defined and where the Y is a -CO₂R¹³ group (in which R¹³ is alkyl, alkenyl or arylalkyl). The hydrolysis may conveniently be carried out by alkaline hydrolysis using a base, such as an alkali metal hydroxide, e.g. lithium hydroxide, or an alkali metal carbonate, e.g. potassium carbonate, in the presence of an aqueous/organic solvent mixture, using organic solvents such as dioxan, tetrahydrofuran or methanol, at a temperature from about ambient to about reflux. The hydrolysis of the esters may also be carried out by acid hydrolysis using an inorganic acid, such as hydrochloric acid, in the presence of an aqueous/inert organic solvent mixture, using organic solvents such as dioxan or tetrahydrofuran, at a temperature from about 50°C to about 80°C.


As another example compounds of formula (I) wherein Het, R¹, R², L¹, L² and Z¹ are as hereinbefore defined, and Y is carboxy may be prepared by acid catalysed removal of the tert-butyl group of tert-butyl esters of formula (I) wherein Het, R¹, R², L¹, L² and Z¹ are as hereinbefore defined and Y is a -CO₂R¹³ group (in which R¹³ is tert-butyl), using standard reaction conditions, for example reaction with trifluoroacetic acid at a temperature at about room temperature.

As another example compounds of formula (I) wherein Het, R¹, R², L¹, L² and Z¹ are as hereinbefore defined and Y is carboxy may be prepared by hydrogenation of compounds of formula (I) wherein Het, R¹, R², L¹, L² and Z¹ are as hereinbefore defined and Y is a -CO₂R¹³ group (in which R¹³ is benzyl). The reaction may be carried out in the presence of ammonium formate and a suitable metal catalyst, e.g. palladium, supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol and at a temperature at about reflux temperature. The reaction may alternatively be carried out in the presence of a suitable metal catalyst, e.g. platinum or palladium optionally supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol.

Esters of formula (I) wherein Het, R¹, R², L² and Z¹ are as hereinbefore defined L¹ is a -R⁶-R⁷- linkage (in which R⁶ is as hereinbefore defined and R⁷ is -C(=O)-NR⁵-) and Y is a -CO₂R¹³ group (in which R¹³ is as hereinbefore defined) may be prepared by reaction of compounds of formula (II):-



wherein Het, R¹, R⁶ and Z¹ are as hereinbefore and X¹ is a hydroxy group or a halogen, preferably chlorine, atom, with amines of formula (III):-




wherein R⁵, R², R¹³ and L² are as hereinbefore defined. When X¹ is a hydroxy group the reaction may be carried out using standard peptide coupling procedures for example coupling in the presence of O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate and triethylamine (or diisopropylethylamine) in tetrahydrofuran (or dimethylformamide), at room temperature. When X¹ is a halogen atom the acylation reaction may be carried out with the aid of a base, such pyridine, preferably in a solvent such as tetrahydrofuran and at a temperature at about room temperature.

Esters of formula (I) wherein Het, R¹, R², L² and Z¹ are as hereinbefore defined L¹ is a -R⁶-R⁷- linkage [in which R⁶ is as hereinbefore defined, and R⁷ is -NR⁵-C(=O)- (where R⁵ is as

hereinbefore defined)] and Y is a $-\text{CO}_2\text{R}^{13}$ group (in which R^{13} is as hereinbefore defined) may be prepared by reaction of compounds of formula (IV):-



wherein Het, R^1 , R^5 , R^6 and Z^1 are as hereinbefore, with compounds of formula (V):-




- 10 wherein R^2 , R^{13} and L^2 are as hereinbefore defined and X^2 is a hydroxy group or a halogen, preferably chlorine, atom, using procedures described hereinbefore for coupling acids or acid halides with amines.

- 15 Esters of formula (I) wherein Het, R^1 , R^2 , L^2 and Z^1 are as hereinbefore defined, L^1 is a $-\text{R}^6-\text{R}^7-$ linkage (in which R^6 is as hereinbefore defined and R^7 is $-\text{O}-$) and Y is a $-\text{CO}_2\text{R}^{13}$ group (in which R^{13} is as hereinbefore defined) may be prepared by reaction of compounds of formula (VI):-




20 wherein Het, R^1 , R^6 and Z^1 are as hereinbefore defined with compounds of formula (VII):-



- 25 wherein R^2 , R^{13} and L^2 are as hereinbefore defined and Z^3 is O, in the presence of a dialkyl azodicarboxylate, such as diethyl azodicarboxylate, and triphenylphosphine, preferably in a dry ethereal solvent, e.g. diethyl ether or tetrahydrofuran, preferably at or near room temperature.

Alternatively esters of formula (I) wherein Het, R¹, R², L² and Z¹ are as hereinbefore defined, L¹ is a -R⁶-R⁷- linkage (in which R⁶ is as hereinbefore defined and R⁷ is -O-) and Y is a -CO₂R¹³ group (in which R¹³ is as hereinbefore defined) may be prepared by alkylation of compounds of formula (VII), wherein R², R¹³ and L² are as hereinbefore defined and Z³ is O with the appropriate alkyl bromides of formula (VIII):-




Het, R¹, R⁶ and Z¹ are as hereinbefore defined and X³ is a halogen, preferably bromo, atom using standard alkylation conditions. The alkylation may for example be carried out in the presence of a base, such as an alkali metal carbonate, e.g. potassium carbonate, or alkali metal hydride, e.g. sodium hydride, in dimethylformamide, or dimethyl sulphoxide, at a temperature from about 0°C to about 100°C.

Esters of formula (I) wherein Het, R¹, R², L² and Z¹ are as hereinbefore defined, L¹ is a -R⁶-R⁷- linkage (in which R⁶ is as hereinbefore defined and R⁷ is -S-) and Y is a -CO₂R¹³ group (in which R¹³ is as hereinbefore defined) may be similarly prepared by alkylation of compounds of formula (VII) wherein R², R¹³ and L² are as hereinbefore defined and Z³ is S.

Esters of formula (I) wherein Het, R¹, R², L² and Z¹ are as hereinbefore defined, L¹ is a -R⁶-R⁷- linkage [in which R⁶ is as hereinbefore defined and R⁷ is -NR⁵- (where R⁵ is as hereinbefore defined)] and Y is a -CO₂R¹³ group (in which R¹³ is as hereinbefore defined) may be similarly prepared by alkylation of compounds of formula (III), wherein R², R⁵, R¹³ and L² are as hereinbefore defined.

Esters of formula (I) wherein Het, R¹, R², L² and Z¹ are as hereinbefore defined, L¹ is a -R⁶-R⁷- linkage [in which R⁶ is alkylene and R⁷ is -C(=O)-] and Y is a -CO₂R¹³ group (in which R¹³ is as hereinbefore defined) may be prepared by reaction of acid chlorides of formula (II) wherein Het, R¹ and Z¹ are as hereinbefore defined, X¹ is chloro and R⁶ is alkylene, with compounds of formula (IX):-




wherein R^2 , R^{13} and L^2 are as hereinbefore defined, by the application or adaptation of the methodology described by R.D.Rieke et al, Synth.Comm., 1995, 23, pages 3923-3930.

5

Esters of formula (I) wherein Het, R^1 , R^2 , L^2 and Z^1 are as hereinbefore defined, L^1 is a $-R^6-R^7-$ linkage [in which R^6 is as hereinbefore defined and R^7 is $-NR^5-C(=O)-NH-$ (where R^5 is as hereinbefore defined)] and Y is a $-CO_2R^{13}$ group (in which R^{13} is as hereinbefore defined)

may be prepared by reaction of compounds of formula (IV) wherein Het, R^1 , R^5 , R^6 and Z^1 are as hereinbefore defined, with isocyanates of formula (X):-

10




wherein R^2 , R^{13} and L^2 are as hereinbefore defined. The reaction is preferably carried out with the aid of a base, such as a tertiary amine, for example triethylamine, preferably in a solvent such as dichloromethane, and at a temperature at about room temperature.

15

Esters of formula (I) wherein Het, R^1 , R^2 , L^2 and Z^1 are as hereinbefore defined, L^1 is a $-R^6-R^7-$ linkage [in which R^6 is as hereinbefore defined and R^7 is $-NH-C(=O)-NR^5-$ (where R^5 is as hereinbefore defined)] and Y is a $-CO_2R^{13}$ group (in which R^{13} is as hereinbefore defined)

20


may be similarly prepared by reaction of amines of formula (III) wherein R^2 , R^5 , R^{13} and L^2 are as hereinbefore defined with compounds of formula (XI):-



25


wherein Het, R^1 , R^6 and Z^1 are as hereinbefore defined.

Esters of formula (I) wherein Het, R¹, R², L² and Z¹ are as hereinbefore defined, L¹ is a -R⁶-R⁷- linkage [in which R⁶ is as hereinbefore defined and R⁷ is -SO₂-NR⁵- (where R⁵ is as hereinbefore defined)] and Y is a -CO₂R¹³ group (in which R¹³ is as hereinbefore defined) may be prepared by reaction of compounds of formula (XII):-



wherein Het, R¹, R⁶ and Z¹ are as hereinbefore defined, with amines of formula (III) wherein R², R⁵, R¹³ and L² are as hereinbefore defined. The reaction is preferably carried out with the aid of a base, such as a tertiary amine, for example triethylamine, preferably in a solvent such as tetrahydrofuran and at a temperature at about room temperature.

Esters of formula (I) wherein Het, R¹, R², L¹, L² and Z¹ are as hereinbefore defined, L¹ is a -R⁶-R⁷- linkage [in which R⁶ is as hereinbefore defined and R⁷ is -NR⁵-SO₂- (where R⁵ is as hereinbefore defined)] and Y is a -CO₂R¹³ group (in which R¹³ is as hereinbefore defined) may be similarly prepared by reaction of compounds of formula (IV) wherein Het, R¹, R⁶, R⁵ and Z¹ are as hereinbefore defined with sulphonyl chlorides of formula (XIII):-



wherein R², R¹³ and L² are as hereinbefore defined.

Esters of formula (I) wherein Het, R¹, R², L² and Z¹ are as hereinbefore defined, L¹ is a -R⁶-R⁷- linkage [in which R⁶ is as hereinbefore defined and R⁷ is -O-C(=O)-] and Y is a -CO₂R¹³ group (where R¹³ is as hereinbefore defined) may be prepared by O-acylation of compounds of formula (VI) wherein Het, R¹, R⁶, and Z¹ are as hereinbefore defined with compounds of formula (V) wherein R², R¹³ and L² are as hereinbefore defined and X² is a chlorine atom. The reaction may be carried using standard O-acylation conditions, for example

reaction in the presence of a base, such as triethylamine or pyridine, at a temperature from about 0°C to about room temperature.

Esters of formula (I) wherein Het, R¹, R², L² and Z¹ are as hereinbefore defined, L¹ is a
5 -R⁶-R⁷- linkage [in which R⁶ is as hereinbefore defined and R⁷ is -C(=O)-O-] and Y is a
-CO₂R¹³ group (where R¹³ is as hereinbefore defined) may be similarly prepared by

O-acylation of compounds of formula (VII) wherein R², R¹³ and L² are as hereinbefore defined
and Z³ is O with compounds of formula (II) wherein Het, R¹, R⁶ and Z¹ are as hereinbefore
defined and X¹ is a chlorine atom.

10

Esters of formula (I) wherein Het, R¹, R², L¹, L² and Z¹ are as hereinbefore defined, L¹ is a
-R⁶-R⁷- linkage (in which R⁶ is as hereinbefore defined and R⁷ is -O-C(=O)-NH-) and Y is a
-CO₂R¹³ group (where R¹³ is as hereinbefore defined) may be prepared by reaction of

compounds of formula (VI) wherein Het, R¹, R⁶ and Z¹ are as hereinbefore defined with

15 isocyanates of formula (XI) wherein R², R¹³ and L² are as hereinbefore defined The reaction is
preferably carried out with the aid of a base, such as a tertiary amine, for example triethylamine,
preferably in a solvent such as dichloromethane, and at a temperature at about room
temperature.


20 Esters of formula (I) wherein Het, R¹, R², L¹, L² and Z¹ are as hereinbefore defined, L¹ is a
-R⁶-R⁷- linkage (in which R⁶ is as hereinbefore defined and R⁷ is -NH-C(=O)-O-) and Y is a
-CO₂R¹³ group (where R¹³ is as hereinbefore defined) may be similarly prepared by reaction of
isocyanates of formula (XI) wherein Het, R¹, R⁶ and Z¹ are as hereinbefore defined with
compounds of formula (VII) wherein R², R¹³ and L² are as hereinbefore defined and Z³ is O.

25


Esters of formula (I) wherein Het, R¹, R², L² and Z¹ are as hereinbefore defined, L¹ is a
-R⁶-R⁷- linkage (in which R⁷ is a direct bond and R⁶ is a straight or branched chain

C₂₋₆alkenylene chain where the carbon-carbon double bond is directly attached to the phenyl
ring containing the -L²-CO₂R¹³ group) may be prepared by reaction of compounds of formula

30 (XIV):-



wherein R^2 , R^{13} and L^2 are as hereinbefore defined, with an appropriate phosphorane (or phosphonate ester) of formula (XV):-



wherein Het, R^1 and Z^1 are as hereinbefore defined, R^6 is a straight or branched chain C_{1-5} alkylene chain and X^5 is $=\text{PPh}_3^+\text{Br}^-$ (or $-\text{P}(=\text{O})(\text{OEt})_2$), using standard Wittig (or Horner-Wadsworth-Emmons) coupling procedures (for example those described in Tetrahedron Organic Chemistry Series Volume 11, Organic Synthesis Based On Name Reactions and Unnamed reactions, Editors, J. E. Baldwin and P. D. Magnus, pages 181 and 421).

Esters of formula (I), wherein Het, R^1 , R^2 , L^1 and Z^1 are as hereinbefore defined, Y is $-\text{CO}_2\text{R}^{13}$ and L^2 is an alkylene linkage substituted by $-\text{NY}^3\text{Y}^4$ (in which one of Y^3 and Y^4 is hydrogen and the other is alkyl, or alkyl substituted by alkoxy, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, hydroxy, oxo, $-\text{NY}^1\text{Y}^2$, or one or more $-\text{CO}_2\text{R}^8$ or $-\text{C}(=\text{O})-\text{NY}^1\text{Y}^2$ groups), may be prepared by reaction of esters of formula (I), wherein Het, R^1 , R^2 , L^1 and Z^1 are as hereinbefore defined, Y is $-\text{CO}_2\text{R}^{13}$ and L^2 is an alkylene linkage substituted by $-\text{NH}_2$, with aldehydes of formula (XVI):-



wherein R^{14} is hydrogen or alkyl, or alkyl substituted by alkoxy, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, hydroxy, oxo, $-\text{NY}^1\text{Y}^2$, or one or more $-\text{CO}_2\text{R}^8$ or $-\text{C}(=\text{O})-\text{NY}^1\text{Y}^2$ groups in the presence of sodium cyanoborohydride. The reaction may be conveniently carried out in methanol, optionally in the presence of sodium acetate and 4Å molecular sieves, and at a temperature at about room temperature.

Esters of formula (I), wherein Het, R¹, R², L¹ and Z¹ are as hereinbefore defined, Y is -CO₂R¹³ and L² contains a -N(R⁸)-C(=O)-R⁹ group, may be prepared by reaction of amines of formula (I), wherein Het, R¹, R², L¹ and Z¹ are as hereinbefore defined, Y is -CO₂R¹³ and L² contains a -NH(R⁸) group, with compounds of formula (XVII):-

5



wherein R⁹ is as hereinbefore defined and X⁵ is a hydroxy group or a halogen, preferably chlorine, atom. When X⁵ is a hydroxy group the reaction may be carried out using standard peptide coupling procedures as described hereinbefore. When X⁵ is a halogen atom the reaction may be carried out with the aid of a base, such as pyridine, preferably in a solvent such as tetrahydrofuran and at a temperature at about room temperature.

Esters of formula (I), wherein Het, R¹, R², L¹ and Z¹ are as hereinbefore defined Y is -CO₂R¹³ and L² contains a -N(R⁸)-C(=O)-OR⁹ group, may be prepared by reaction of amines of formula (I), wherein Het, R¹, R², L¹ and Z¹ are as hereinbefore defined, Y is -CO₂R¹³ and L² contains a -NH(R⁸) group, with the appropriate chloroformate, e.g. ethyl (or benzyl) chloroformate compounds, according to standard reaction conditions.

Esters of formula (I), wherein Het, R¹, R², L¹ and Z¹ are as hereinbefore defined Y is -CO₂R¹³ and L² contains a -N(R⁸)-SO₂-R⁹ group, may be prepared by reaction of amines of formula (I), wherein Het, R¹, R², L¹ and Z¹ are as hereinbefore defined, Y is -CO₂R¹³ and L² contains a -NH(R⁸) group, with the appropriate sulphonyl chloride, e.g. an aryl(or heteroaryl)sulphonyl chloride, such as phenyl(or pyridyl)sulphonyl chloride, according to standard reaction conditions.

Esters of formula (I), wherein Het, R¹, R², L¹ and Z¹ are as hereinbefore defined Y is -CO₂R¹³ (in which R¹³ is alkyl) and L² is a $\begin{array}{c} -CH-CH_2- \\ | \\ NH_2 \end{array}$ linkage, may be prepared by hydrogenation of

esters of formula (I), wherein Het, R¹, R², L¹ and Z¹ are as hereinbefore defined, Y is -CO₂R¹³


(in which R^{13} is alkyl) and L^2 is a $\begin{array}{c} -\text{CH}-\text{CH}_2- \\ | \\ \text{N}(\text{CH}_2\text{Ph})_2 \end{array}$ linkage. The reaction may be carried out in

the presence of formic acid and a suitable metal catalyst, e.g. palladium, supported on an inert carrier such as carbon, at a temperature at about 60°C. The reaction may conveniently be carried out in the presence of a suitable metal catalyst, e.g. platinum or palladium optionally supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol.

Esters of formula (I), wherein Het, R^1 , R^2 , L^1 and Z^1 are as hereinbefore defined Y is $-\text{CO}_2R^{13}$

(in which R^{13} is alkyl) and L^2 is a $\begin{array}{c} -\text{CH}-\text{CH}_2- \\ | \\ \text{NH}_2 \end{array}$ linkage, may be similarly prepared by

- 10 hydrogenation of esters of formula (I), wherein Het, R^1 , R^2 , L^1 and Z^1 are as hereinbefore defined, Y is $-\text{CO}_2R^{13}$ (in which R^{13} is alkyl) and L^2 is a



Esters of formula (I), wherein Het, R^1 , R^2 , L^1 and Z^1 are as hereinbefore defined Y is $-\text{CO}_2R^{13}$

and L^2 is a $\begin{array}{c} -\text{CH}-\text{CH}_2- \\ | \\ \text{NH}_2 \end{array}$ (or $\begin{array}{c} -\text{CH}-\text{CH}_2- \\ | \\ \text{NH}_2 \end{array}$) linkage, may also be obtained following


- 15 standard recrystallisation of salts of the racemic mixture, for example recrystallisation of the tartrate salt.

Esters of formula (I), wherein Het, R^1 , R^2 , L^1 and Z^1 are as hereinbefore defined Y is $-\text{CO}_2R^{13}$


and L^2 is a $\begin{array}{c} -\text{CH}-\text{CH}_2- \\ | \\ \text{NH}_2 \end{array}$ (or $\begin{array}{c} -\text{CH}-\text{CH}_2- \\ | \\ \text{NH}_2 \end{array}$) linkage, may also be obtained by the

- 20 application of standard enzymatic resolution procedures for example those described by Soloshonok, V. A., et.al., Tetrahedron: Asymmetry 6 (1995) 7, 1601-1610.

Esters of formula (I) wherein Het, R¹, R², L¹ and Z¹ are as hereinbefore defined Y is -CO₂R¹³ and L² is a $\text{—CH—CH}_2\text{—}$ or $\text{—CH—CH}_2\text{—}$ linkage, may be prepared by reaction



of compounds of formula (XVIII):-




(XVIII)


wherein Het, R¹, R², L¹ and Z¹ are as hereinbefore defined and Y is -CO₂R¹³, with an alkali metal hydride, such as sodium hydride, in an inert solvent, e.g. tetrahydrofuran, and at a temperature at about room temperature, and subsequent reaction with the anion derived from treating dibenzylamine, or (*S*)-N-benzyl- α -methylbenzylamine, with butyllithium, at a temperature at about -78°C.

In a process A compounds of formula (I), containing an amide bond may be prepared by coupling of an acid (or an acid halide) with an amine to give an amide bond using standard peptide coupling procedures as described hereinafter.

As an example of process A, compounds of formula (I) wherein R¹, R², Z¹ and Het are as hereinbefore defined, L¹ represents -R⁶-R⁷- (in which R⁶ is as hereinbefore defined and R⁷ is -C(=O)-NH-), L² contains a -N(R⁸)-C(=O)-R⁹ group (in which R⁸ and R⁹ are as hereinbefore defined) and Y is carboxy may be prepared by :-


- (i) treating bromo-Wang resin (4-bromomethylphenoxyated styrene/divinylbenzene copolymer) with an acid of formula (XXI) wherein R² is as hereinbefore defined and L² contains a -N(R⁸)-R¹⁵ group in which R¹⁵ is a suitable imino-protecting group, such as 9H-fluoren-9-ylmethoxycarbonyl, in the presence of a tertiary amine, such as diisopropylethylamine, and cesium iodide, in an inert solvent, such as dimethylformamide, at a temperature at about room temperature, to give Resin 1 wherein R² is as hereinbefore defined, L² contains a -N(R⁸)-R¹⁵ group

(in which R^{15} is as just defined) and  represents the polymeric core comprising polystyrene crosslinked with 1% to 2% divinylbenzene;




- (ii) treatment of Resin 1 in which L^2 contains a $-N(R^8)-R^{15}$ group with piperidine in an inert solvent, such as dimethylformamide, and at a temperature at about room temperature to give Resin 6 in which L^2 contains a $-N(R^8)H$ group;
- (iii) reaction of Resin 1 in which L^2 contains a $-N(R^8)H$ group with compounds of formula (XVII) wherein R^9 and X^1 are as hereinbefore defined and is a hydroxy group or a halogen, preferably chlorine, atom to give Resin 1 in which L^2 contains a $-N(R^8)-C(=O)-R^9$ group [When X^1 is a hydroxy group the reaction may be carried out using standard peptide coupling procedures for example coupling in the presence of O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate and triethylamine (or diisopropylethylamine) in tetrahydrofuran (or dimethylformamide), at room temperature. When X^1 is a halogen atom the acylation reaction may be carried out with the aid of a base, such pyridine, preferably in a solvent such as tetrahydrofuran and at a temperature at about room temperature];

- (iv) treatment of Resin 1 in which L^2 contains a $-N(R^7)-C(=O)-R^8$ group with a solution of tin (II) chloride in dimethylformamide to give Resin 2 wherein R^2 and \bullet are as hereinbefore defined and L^2 contains a $-N(R^8)-C(=O)-R^9$ group (in which R^8 and R^9 are as hereinbefore defined);



- (v) reaction of Resin 2 with acids of formula (II) wherein R^1 , R^6 , Z^1 and Het is as hereinbefore defined, X^1 is hydroxy, using peptide coupling conditions, for example those described hereinbefore, to give Resin 3 wherein R^1 , R^2 , R^6 , Z^1 , Het and P are as hereinbefore defined and L^2 contains a $-N(R^8)-C(=O)-R^9$ group (in which R^8 and R^9 are as hereinbefore defined) ;



- (vi) treatment of Resin 3 with trifluoroacetic acid in an inert solvent, such as dichloromethane, and at a temperature at about room temperature.

According to a further feature of the present invention, compounds of the invention may be prepared by interconversion of other compounds of the invention.

- 10 For example compounds of formula (I) wherein Het, R¹, R², L¹, L² and Z¹ are as hereinbefore defined and Y is -C(=O)-NHOH, may be prepared by reaction of compounds of formula (I) wherein Het, R¹, R², L¹, L² and Z¹ are as hereinbefore defined and Y is carboxy, with hydroxylamine using standard peptide coupling procedures such as treatment with a carbodiimide, for example dicyclohexylcarbodiimide, in the presence of triethylamine, in an inert solvent such as dichloromethane or tetrahydrofuran and at a temperature at about room temperature. The coupling may also be carried out using 1-hydroxybenzotriazole and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide in dichloromethane at room temperature. The preparation may also be carried out using an O-protected hydroxylamine such as O-(trimethylsilyl)hydroxylamine, O-(t-butyldimethylsilyl)-hydroxylamine, or O-(tetrahydropyranyl)hydroxylamine followed by treatment with acid.

- As another example of the interconversion process, compounds of formula (I) wherein Het, R¹, R², L¹, Z¹ and Y are as hereinbefore defined and L² is an optionally substituted alkylene linkage, may be prepared by hydrogenation of the corresponding compounds of formula (I) in which L² is the corresponding optionally substituted alkenylene linkage. The hydrogenation

may be carried out using hydrogen (optionally under pressure) in the presence of a suitable metal catalyst, e.g. platinum or palladium optionally supported on an inert carrier such as carbon, preferably in a solvent such as methanol or ethanol, and at a temperature at about room temperature.

5

As another example of the interconversion process, compounds of formula (I) wherein Het, R¹, R², L², Z¹ and Y are as hereinbefore described and L¹ is a -R⁶-R⁷- linkage where R⁶ is a straight or branched chain C₂₋₆alkylene chain and R⁷ is a direct bond, may be similarly prepared by hydrogenation of the corresponding compounds of formula (I) in which L¹ is a
10 -R⁶-R⁷- linkage where R⁶ is a straight or branched chain C₂₋₆alkenylene chain and R⁷ is a direct bond.

As another example of the interconversion process, compounds of the invention containing a heterocyclic group wherein the hetero atom is a nitrogen atom may be oxidised to their
15 corresponding N-oxides. The oxidation may conveniently be carried out by means of reaction with a mixture of hydrogen peroxide and an organic acid, e.g. acetic acid, preferably at or above room temperature, for example at a temperature of about 60-90°C. Alternatively, the oxidation may be carried out by reaction with a peracid, for example peracetic acid or
20 m-chloroperoxybenzoic acid, in an inert solvent such as chloroform or dichloromethane, at a temperature from about room temperature to reflux, preferably at elevated temperature. The oxidation may alternatively be carried out by reaction with hydrogen peroxide in the presence of sodium tungstate at temperatures between room temperature and about 60°C.

It will be appreciated that compounds of the present invention may contain asymmetric centres.
25 These asymmetric centres may independently be in either the R or S configuration. It will be apparent to those skilled in the art that certain compounds of the invention may also exhibit geometrical isomerism. It is to be understood that the present invention includes individual geometrical isomers and stereoisomers and mixtures thereof, including racemic mixtures, of compounds of formula (I) hereinabove. Such isomers can be separated from their mixtures, by
30 the application or adaptation of known methods, for example chromatographic techniques and recrystallisation techniques, or they are separately prepared from the appropriate isomers of their intermediates.

According to a further feature of the invention, acid addition salts of the compounds of this invention may be prepared by reaction of the free base with the appropriate acid, by the application or adaptation of known methods. For example, the acid addition salts of the compounds of this invention may be prepared either by dissolving the free base in water or aqueous alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.


The acid addition salts of the compounds of this invention can be regenerated from the salts by the application or adaptation of known methods. For example, parent compounds of the invention can be regenerated from their acid addition salts by treatment with an alkali, e.g. aqueous sodium bicarbonate solution or aqueous ammonia solution.

Compounds of this invention can be regenerated from their base addition salts by the application or adaptation of known methods. For example, parent compounds of the invention can be regenerated from their base addition salts by treatment with an acid, e.g. hydrochloric acid.


Compounds of the present invention may be conveniently prepared, or formed during the process of the invention, as solvates (e.g. hydrates). Hydrates of compounds of the present invention may be conveniently prepared by recrystallisation from an aqueous/organic solvent mixture, using organic solvents such as dioxan, tetrahydrofuran or methanol.

According to a further feature of the invention, base addition salts of the compounds of this invention may be prepared by reaction of the free acid with the appropriate base, by the application or adaptation of known methods. For example, the base addition salts of the compounds of this invention may be prepared either by dissolving the free acid in water or aqueous alcohol solution or other suitable solvents containing the appropriate base and isolating the salt by evaporating the solution, or by reacting the free acid and base in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.

The starting materials and intermediates may be prepared by the application or adaptation of known methods, for example methods as described in the Reference Examples or their obvious chemical equivalents.

Acids of formula (II) wherein Het is , R^1 and R^6 are as hereinbefore defined, Z^1

is NH and X^1 is hydroxy may be prepared by reaction of compounds of formula (XIX):-




(XIX)

5

wherein R^6 and R^{13} are as hereinbefore defined, and X is O, with isothiocyanates of formula $R^1-N=C=S$ in ethanol and at room temperature, followed by reaction with a carbodiimide, such as dicyclohexylcarbodiimide or diisopropylcarbodiimide in ethanol and at a temperature from about room temperature to about reflux temperature, and subsequent conversion of the ester

10 group to an acid group (for example when R^{13} is alkyl by hydrolysis using standard conditions, as described hereinbefore).

Acids of formula (II) wherein Het is , R^1 and R^6 are as hereinbefore defined, Z^1

is NH and X^1 is hydroxy may be similarly prepared from compounds of formula (XIX) wherein

15 R^6 and R^{13} are as hereinbefore defined and X is NH.

Acid chlorides of formula (II) wherein Het, R^1 , R^6 and Z^1 are as hereinbefore defined and X^1 is a chlorine atom may be prepared from the corresponding acids of formula (II) wherein Het, R^1 , R^6 and Z^1 are as hereinbefore defined and X^1 is hydroxy, by the application of standard

20 procedures for the conversion of acids to acid chlorides for example by reaction with oxalyl chloride.


Acid chlorides of formula (V) wherein R^2 , R^{13} and L^2 are as hereinbefore defined and X^2 is a chlorine atom may be similarly prepared from the corresponding acids of formula (V) wherein

25 R^2 , R^{13} and L^2 are as hereinbefore defined and X^2 is hydroxy.

Compounds of formula (III) wherein R^2 , R^{13} and L^2 are as hereinbefore defined and R^5 is methyl may be prepared by treatment of the corresponding compounds of formula (III) wherein R^2 , R^{13} and L^2 are as hereinbefore defined and R^5 is hydrogen with formic acetic anhydride followed by reduction with lithium aluminium hydride according to the procedure described by L. G. Humber L G et al, J Med Chem, 1971, 14, page 982.


Compounds of formula (IV) wherein Het, R^1 , R^6 and Z^1 are as hereinbefore defined and R^5 is methyl may be similarly prepared by reacting compounds of formula (IV) wherein Het, R^1 , R^6 and Z^1 are as hereinbefore defined and R^5 is hydrogen.

Compounds of formula (III) wherein R^2 , R^{13} , L^2 and R^5 are as hereinbefore defined may be prepared by reaction of compounds of formula (XX):-



wherein R^2 , R^{13} , L^2 and R^5 are as hereinbefore defined and R^{15} is an acid-labile protecting group, such as tertiary-butyloxycarbonyl, with trifluoroacetic acid, in an inert solvent, such as dichloromethane and at a temperature at about room temperature. This method is particularly suitable for the preparation of compounds of formula (III) where R^5 is methyl.

Compounds of formula (III) wherein R^2 , R^{13} and L^2 are as hereinbefore defined and R^5 is hydrogen may be prepared by reduction of the corresponding nitro compounds of formula (XXI):-



wherein R^2 , R^{13} and L^2 are as hereinbefore defined. The reduction may be carried out using iron powder and ammonium chloride, in aqueous ethanol at a temperature at about reflux.

Compounds of formula (XIX) wherein R^6 and R^{13} are as hereinbefore defined and X is NH may be similarly prepared by reduction of the corresponding nitro-amino compounds or dinitro compounds.


5

Compounds of formula (IV) wherein Het, R^1 , R^6 and Z^1 are as hereinbefore defined and R^5 is hydrogen may be prepared by reaction of compounds of formula (VIII) wherein Het, R^1 , R^6 and Z^1 are as hereinbefore defined and X^3 is bromo with phthalimide potassium salt in dimethylformamide followed by reaction with hydrazine hydrate in ethanol (for example using the conditions described by O. Diouf et al., Heterocycles, 1995, 41, page 1219-1233).

10

Compounds of formula (VI) wherein Het, R^1 and Z^1 are as hereinbefore defined and R^6 is methylene (or a C_{2-6} straight or branched alkylene chain), may be prepared by reduction of esters of formula (XXII):-

15




wherein Het, R^1 and Z^1 are as hereinbefore defined, R^{13} is alkyl and R^{16} is a direct bond (or a C_{1-5} straight or branched alkylene chain). The reduction may conveniently be carried out with diisobutylaluminium hydride in an inert solvent, such as tetrahydrofuran, at a temperature from about -78°C to about room temperature. The reduction may also be carried out with lithium aluminium hydride in an inert solvent, such as an ether, for example diethyl ether, at a temperature from about room temperature to about reflux.

20

Compounds of formula (VII) wherein R^2 , R^{13} and L^2 are as hereinbefore defined and Z^3 is O may be prepared from the corresponding acids of formula (XXIII):-

25



wherein R^2 and L^2 are as hereinbefore defined and Z^3 is O, by standard esterification procedures for example reaction with a lower alkyl alcohol (e.g. methanol) in the presence of an acid catalyst, such as hydrogen chloride or sulphuric acid.

5 Compounds of formula (VIII) wherein Het, R^1 and Z^1 are as hereinbefore defined, R^6 is an alkylene chain and X^3 is bromo may be prepared by reaction of compounds of formula (VI) wherein Het, R^1 and Z^1 are as hereinbefore defined, R^6 is an alkylene chain with phosphorus tribromide in an inert solvent such as carbon tetrachloride and at a temperature at about room temperature.

10

Compounds of formula (X) wherein R^2 , R^{13} and L^2 are as hereinbefore defined may be prepared from compounds of formula (III) wherein R^2 , R^{13} and L^2 are as hereinbefore defined and R^5 is hydrogen with phosgene following standard reaction conditions for the conversion of amines to isocyanates.

15

Compounds of formula (XI) wherein Het, R^1 , R^6 and Z^1 are as hereinbefore defined may be similarly prepared from compounds of formula (IV) wherein Het, R^1 , R^6 and Z^1 are as hereinbefore defined and R^5 is hydrogen.

20 Compounds of formula (XII) wherein Het, R^1 , R^6 and Z^1 are as hereinbefore defined may be prepared from compounds of formula (VIII) wherein Het, R^1 , R^6 and Z^1 are as hereinbefore defined and X^3 is bromo by reaction with sodium sulphite followed by phosphorus trichloride according to the described by P.N.Culshaw and J.C.Walton, J.Chem Soc, Perkin Trans II, 1991, 8, pages1201-1208.

25

Compounds of formula (XIII) wherein R^2 , R^{13} and L^2 are as hereinbefore defined may be prepared from compounds of formula (III) wherein R^2 , R^{13} and L^2 are as hereinbefore defined and R^5 is hydrogen by standard procedures for the conversion of anilines to the corresponding phenylsulphonyl chlorides.

30

Compounds of formula (XV) wherein Het, R^1 and Z^1 are as hereinbefore defined, R^6 is a straight or branched chain C_{1-5} alkylene chain and X^5 is $=PPh_3^+Br^-$ may be prepared by

reaction of compounds of formula (VIII) wherein Het, R¹ and Z¹ are as hereinbefore defined, R⁶ is a straight or branched chain C₁₋₅alkylene chain and X³ is a bromine atom by reaction with triphenylphosphine in an inert solvent and at a temperature from about room temperature to about reflux temperature of the solvent.

5

Compounds of formula (XX) wherein Het, R¹, R¹¹ and Z¹ are as hereinbefore defined and R⁹ is alkyl may be similarly prepared from the corresponding acids.

Compounds of formula (X) wherein R², R⁹ and L² are as hereinbefore defined may be prepared from bromo-iodobenzene by the adaptation of procedures described by Y. Tamaru et al, Tetrahedron Letters, 1985, 26, page 5559 and 1986, 27, page 955.

Compounds of formula (XX) wherein R², R¹³ are as hereinbefore defined, R⁵ is methyl, R¹⁵ is an acid-labile protecting group, such as tertiary-butyloxycarbonyl, and L² is an alkylene linkage substituted by -NY³Y⁴ (in which one of Y³ and Y⁴ is hydrogen and the other is alkyl, or alkyl substituted by alkoxy, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, hydroxy, oxo, -NY¹Y², or one or more -CO₂R⁸ or -C(=O)-NY¹Y² groups), may be prepared by reaction of compounds of formula (XX) wherein R², R⁵, R¹³ and R¹⁵ are as defined immediately above, and L² is an alkylene linkage substituted by -NH₂, with aldehydes of formula (XVI) wherein R¹⁴ is as hereinbefore defined in the presence of sodium cyanoborohydride.

Compounds of formula (XX) wherein R², R¹³ and R⁵ are as hereinbefore defined, R¹⁴ is an acid-labile protecting group, such as tertiary-butyloxycarbonyl, and L² contains a -N(R⁸)-C(=O)-R⁹ group, may be prepared by reaction of compounds of formula (XX) wherein R², R⁵, R¹³ and R¹⁵ are as defined immediately above, and L² contains a -NH(R⁸) group, with compounds of formula (XVII) wherein R⁹ is as hereinbefore defined and X⁵ is a hydroxy group or a halogen, preferably chlorine, atom, using standard coupling procedures as described hereinbefore.

Compounds of formula (XX) wherein R², R¹³ and R⁵ are as hereinbefore defined, R¹⁵ is an acid-labile protecting group, such as tertiary-butyloxycarbonyl, and L² contains a -N(R⁸)-C(=O)-OR⁹ group, may be prepared by reaction of compounds of formula (XX) wherein

R², R⁵, R¹³ and R¹⁵ are as defined immediately above, and L² contains a -NH(R⁸) group, with Boc-anhydride, according to standard reaction conditions.


Compounds of formula (XX) wherein R², R¹³ and R⁵ are as hereinbefore defined, R¹⁵ is an acid-labile protecting group, such as tertiary-butyloxycarbonyl, and L² contains a -N(R⁸)-SO₂-R⁹ group, may be prepared by reaction of compounds of formula (XX) wherein R², R⁵, R¹³ and R¹⁵ are as defined immediately above, and L² contains a -NH(R⁸) group, with the appropriate sulphonyl chloride, e.g. an aryl(or heteroaryl)sulphonyl chloride, such as phenyl(or pyridyl)sulphonyl chloride, according to standard reaction conditions.

Compounds of formula (XX) wherein R², R¹³ and R⁵ are as hereinbefore defined, R¹⁵ is an acid-labile protecting group, such as tertiary-butyloxycarbonyl, and L² is a $\begin{array}{c} -\text{CH}-\text{CH}_2- \\ | \\ \text{NHR}^8 \end{array}$, (or

$\begin{array}{c} -\text{CH}-\text{CH}_2- \\ | \\ \text{NHR}^8 \end{array}$) linkage, may be prepared by hydrogenation of compounds of formula (XX)

wherein R², R⁵, R¹³ and R¹⁵ are as defined immediately above, and L² is a $\begin{array}{c} -\text{CH}-\text{CH}_2- \\ | \\ \text{R}^{17}\text{N}-\text{CH}_2\text{Ph} \end{array}$

(or $\begin{array}{c} -\text{CH}-\text{CH}_2- \\ | \\ \text{CH} \\ | \\ \text{CH}_3 \end{array}$) linkage where R¹⁷ is R⁸ or benzyl, using procedures described





hereinbefore.

Compounds of formula (XX) wherein R², R¹³ and R⁵ are as hereinbefore defined, R¹⁵ is an acid-labile protecting group, such as tertiary-butyloxycarbonyl, and L² is a $\begin{array}{c} -\text{CH}-\text{CH}_2- \\ | \\ \text{NH}_2 \end{array}$ (or

$\begin{array}{c} -\text{CH}-\text{CH}_2- \\ | \\ \text{NH}_2 \end{array}$) linkage, may also be obtained following standard recrystallisation of salts of


the racemic mixture or enzymatic resolution procedures, for example those described hereinbefore.

- 5 Compounds of formula (XX) wherein R^2 , R^{13} and R^5 are as hereinbefore defined, R^{15} is an acid-labile protecting group, such as tertiary-butyloxycarbonyl, and L^2 is a



reaction of compounds of formula (XXIV):-

10




wherein R^2 , R^5 , R^{13} and R^{15} are as hereinbefore defined, with an alkali metal hydride, such as sodium hydride, in an inert solvent, e.g. tetrahydrofuran, and at a temperature at about room temperature, and subsequent reaction with the anion derived from treating the appropriate

15 amine, such as dibenzylamine, (S)-N-methyl- α -methylbenzylamine or (S)-N-benzyl- α -methylbenzylamine, using procedures described hereinbefore.

Compounds of formula (XXIV), wherein R^2 , R^5 , R^{13} and R^{15} are as hereinbefore defined may be prepared by reaction of compounds of formula (XXV):-

20



wherein R^2 , R^5 and R^{15} are as hereinbefore defined, with an acrylic acid ester, such as tert-butyl acrylate, in the presence of palladium acetate, a triarylphosphine, such as

tri(2-methylphenyl)phosphine, and a tertiary amine, such as tributylamine, in an inert solvent, such as dimethylformamide and at a temperature up to about 100°C.

Compounds of formula (XXV) wherein R², R⁵ and R¹⁵ are as hereinbefore defined, may be prepared by the application or adaption of procedures described by Ciattini et al, Tetrahedron Letters, 1995,36, pages 4133-4136.

Intermediates of formulae (Resin 1), (Resin 2) and (Resin 3) are novel compounds and, as such, they and their processes described herein for their preparation constitute further features of the present invention.

The present invention is further Exemplified but not limited by the following illustrative Examples and Reference Examples.

High Pressure Liquid Chromatography (HPLC) conditions for determination of retention times (RT) were: 15cm Hypersil Elite C-18 column, ELS detector; solvent acetonitrile/water gradient (both buffered with 0.5 % trifluoroacetic acid): 20% acetonitrile for 3 minutes; then ramp up to 80 % over the next 12 minutes; maintain at 80 % acetonitrile for 3 minutes; then ramp back to 20 % acetonitrile over 0.5 minutes (total run time 20 minutes).

EXAMPLE 1

[R] 3-(Acetyl-methyl-amino)-3-(4-{methyl-[(2-o-tolylamino-benzoxazol-6-yl)-acetyl]-amino}-phenyl)-propionic acid

A solution of 2-o-tolylamino-benzoxazol-6-ylacetic acid (200mg, Reference Example 1) and diisopropylethylamine (260mg) in dimethylformamide (5mL) was treated successively with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (300mg) and then with [R]-tert-butyl 3-(acetylmethylamino)3-[(4-methylamino)phenyl]propionate (250mg, Reference Example 4). After stirring at room temperature for 2 hours the mixture was partitioned between ethyl acetate (100mL) and hydrochloric acid (100mL, 1M). The organic layer was washed with aqueous sodium bicarbonate solution (5%), then dried and then evaporated. The residue was subjected to flash chromatography on silica eluting with ethyl acetate to give a colourless gum (240mg) which was dissolved in trifluoroacetic acid. After standing at room temperature for 2 hours the mixture was evaporated and the residue was triturated with ether to give the title compound (100mg) as a colourless foam . HPLC: RT=11.45 minutes (92%). MS(ES negative): 513 M⁻.

EXAMPLE 2**(R,S) 3-Benzoylamino-3-[4-[2-(2-*o*-tolylamino-benzoxazol-6-yl)-acetylamino]-phenyl]-propionic acid**

5 Step 1: A suspension of Bromo-Wang resin (6.9g, Novabiochem, 1 mmol/g) in the minimum volume of dimethylformamide (about 25mL) was treated with (RS) 3-(9*H*-fluoren-9-ylmethoxycarbonylamino)-3-(4-nitro-phenyl)-propionic acid (3.71g), then with caesium iodide (1.78g), and then with diisopropylethylamine (1.5mL). The mixture was allowed to shake gently at room temperature overnight. The resin was drained and then washed (i) three times with
10 dimethylformamide, (ii) twice with methanol, (iii) three times with tetrahydrofuran, (iv) once with methanol, and (v) once with dichloromethane.

Step 2: The resin from step 1 was treated with a mixture of piperidine and dimethylformamide(30mL, 1:4, v/v) at room temperature for 2 hours. The resin was drained
15 and then washed (i) three times with dimethylformamide, (ii) once with methanol, (iii) once with tetrahydrofuran, (iv) once with methanol, and (v) once with dichloromethane and then dried at room temperature under vacuum.

Step 3: A suspension of the resin from step 2 (615mg) in dimethylformamide (2mL) was treated
20 successively with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (630mg), a solution of benzoic acid (200mg) in dimethylformamide (1mL) and diisopropylethylamine (0.58mL). After standing at room temperature for 4 hours with occasional agitation the resin was drained and then washed (i) four times with dimethylformamide, (ii) once with methanol, (iii) once with tetrahydrofuran, (iv) once with
25 methanol, (v) once with dichloromethane and (vi) once with ether and then dried at room temperature under vacuum. A small portion of this resin (20mg) was treated with a mixture of trifluoroacetic acid and dichloromethane (1:1, v/v) at room temperature for about 45 minutes followed by filtration and evaporation of the filtrate to give **(R,S) 3-Benzoylamino-3-(4-nitrophenyl)-propionic acid**. HPLC: $R_T = 13.3$ minutes (97% by UV @ 200nm). MS: 315
30 (MH⁺).

Step 4: The Resin from step 3 (325mg) was treated with a solution of tin (II) chloride in dimethylformamide (3mL, 2M). After standing at room temperature with occasional agitation for 7 hours the resin was drained and then washed (i) three times with dimethylformamide, (ii)
35 twice with methanol, and (iii) three times with dimethylformamide. The resin was resuspended

in dimethylformamide(5mL) and then treated successively with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (350mg), (2-o-tolylamino-benzoxazol-6-yl)-acetic acid (250mg), and diisopropylethylamine (0.32mL). This mixture was allowed to stand at room temperature overnight. The resin was drained and then washed (i) three times with dimethylformamide, (ii) twice with methanol, and (iii) three times with tetrahydrofuran, (iv) once with methanol and once with dichloromethane.

Step 5. The Resin from step 4 was treated with a mixture of trifluoroacetic acid and dichloromethane (5mL, 1:1, v/v) and the mixture allowed to stand at room temperature with occasional agitation for 1 hour. The resin was then drained and the filtrate was evaporated. The residue was triturated with water to give a yellow solid, which was recrystallised from aqueous ethanol to give the title compound (50mg) as an off-white solid. HPLC: $R_T = 14.0$ minutes (80% by UV @ 220nm). MS: 549(MH⁺).

EXAMPLE 3

(R) 3-[(5-Methyl-isoxazole-3-carbonyl)-amino]-3-{4-[2-(2-o-tolylamino-benzoxazol-6-yl)-acetyl-amino]-phenyl}-propionic acid

A solution of (2-o-tolylamino-benzoxazol-6-yl)-acetic acid (245mg, Reference Example 1), (R) 3-(4-amino-phenyl)-3-[(5-methyl-isoxazole-3-carbonyl)-amino]-propionic acid tert-butyl ester (300mg, Reference Example 10) and O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (360mg) in dimethylformamide (10mL) was treated with diisopropylethylamine (260mg). After standing at room temperature for 3 hours the mixture was partitioned between ethyl acetate (100mL) and acetic acid (100mL, 2M). The organic phase was washed with sodium hydrogen carbonate solution (100mL, 5% w/v) then dried and then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of ethyl acetate and cyclohexane (1:1, v/v). The material obtained was treated with a mixture of trifluoroacetic acid and dichloromethane (10mL, 1:1, v/v). The mixture was kept at room temperature for 2 hours and then evaporated. The residue was triturated with ether to give the title compound (230mg) as a white amorphous powder.

EXAMPLE 4

4-(2-Carboxy-1-{4-[2-(2-o-tolylamino-benzoxazol-5-yl)-acetyl-amino]-phenyl}-ethylcarbamoyl)-butyric acid

A mixture of methyl 4-(2-methoxycarbonyl-1-{4-[2-(2-o-tolylamino-benzoxazol-5-yl)-acetyl-amino]-phenyl}-ethylcarbamoyl)-butyrate (0.31g, Reference Example 12) aqueous sodium

hydroxide solution (2.64ml, 1M) and tetrahydrofuran was heated at reflux temperature for 3 hours. The mixture was then treated with a further aliquot of aqueous sodium hydroxide solution (2.64ml, 1M) and heating at reflux temperature was continued for a further 3 hours. The reaction mixture was evaporated and the residue was dissolved in water. The pH of this solution was adjusted to 1-2 by addition of concentrated hydrochloric acid. The resulting solid was filtered, then washed well with water, then dried and then recrystallised from aqueous isobutanol. The crystalline solid was washed with pentane and then dried at 100°C under vacuum to give the title compound (0.13g) as colourless crystals, m.p. 255.6-257.1°C. [Elemental analysis: Found:- C,64.51; H,5.41; N,10.03; H₂O,1.58%. Calculated for C₃₀H₃₀N₄O₇•0.5H₂O:- C,63.43; H,5.51; N,9.87; H₂O,1.59%].

EXAMPLE 5

(a) (R,S) 3-(4-{2-[2-(2-Methyl-phenylamino)-benzoxazol-6-yl]-acetvlamino}-phenyl)-3-[(5-methylisoxazole-3-carbonyl)-amino]-propionic acid

Step 1. 4-(Bromomethyl)phenoxymethyl polystyrene (10g, 1.0mmol/g) was swollen in dimethylformamide for 30 minutes and then drained. (40ml) was added with N,N-diisopropylethylamine (2.5ml), cesium iodide (2.85g) and N-(9-fluorenylmethoxycarbonyl)-3-amino-3-(4-nitrophenyl)-propionic acid (5.94g). The mixture was agitated overnight, drained and the resin was washed with excess dimethylformamide, then with dichloromethane, then with diethyl ether and then dried under vacuum.

Step 2. The resin from Step 1 (2g) was then swollen in dimethylformamide for 30 minutes and then drained. A solution of piperidine in dimethylformamide (20% v/v; 20ml) was then added and the resin agitated for 2 minutes and then drained. A second portion of piperidine in dimethylformamide (20% v/v; 20ml) was then added and the resin agitated for 2 minutes, drained and the resin washed with excess dimethylformamide.

Step 3. Dimethylformamide (15ml) was added to the resin from Step 2 together with N,N-diisopropylethylamine (1.29g), 5-methylisoxazole-3-carboxylic acid (0.57g) and O-(7-azabenzotriazole-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (1.71g). The mixture was agitated overnight and then the resin was drained, then washed with (i) excess dimethylformamide, (ii) dichloromethane, (iii) diethyl ether and then dried under vacuum.

Step 4. The resin (1.5g) from Step 3 was then swollen in dimethylformamide for 30 minutes, then drained and then treated with a solution of anhydrous tin (ii) chloride in dimethylformamide (2M, 15ml). The mixture was agitated for 7 hours and then drained. The resin was washed with (i) excess dimethylformamide, (ii) dichloromethane (iii) diethyl ether and then dried under vacuum.

Step 5. The resin (1.0g) from Step 4 was then swollen in dimethylformamide for 30 minutes and then drained. Dimethylformamide (10ml) was added to the resin together with N,N-diisopropylethylamine (0.322g), 4-nitro-(3-acetyloxy)phenylacetic acid (0.233g) and O-(7-azabenzotriazole-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate (0.38g). The mixture was agitated for 6 hours. The resin was drained and then washed with excess dimethylformamide.

Step 6. The resin from Step 5 was treated with a solution of piperidine in dimethylformamide (20% v/v; 10ml). After agitating overnight the resin was drained and then washed with excess dimethylformamide.

Step 7. The resin (1.0g) from Step 6 was then swollen in dimethylformamide for 30 minutes, then drained and then treated with a solution of anhydrous tin (ii) chloride in dimethylformamide (2M, 15ml). After agitating for 7 hours the resin was drained and then washed with (i) excess dimethylformamide, (ii) dichloromethane (iii) diethyl ether and then dried under vacuum.

Step 8. The resin (100mg) from Step 7 was treated with o-tolylisothiocyanate (0.12g) and dimethylformamide (2ml). After agitating at 70°C overnight the resin was drained, then washed with excess dimethylformamide and then treated with dimethylformamide (2ml) and N,N'-diisopropylcarbodiimide (0.126g). After agitating at 70°C overnight the resin was drained, then washed with (i) excess dimethylformamide, (ii) dichloromethane (iii) diethyl ether and then dried under vacuum.

Step 9. The resin from Step 8 was then soaked in trifluoroacetic acid and water (9:1) for 45 minutes. The resin was filtered from the solution and the filtrate was evaporated. The residue was subjected to reverse phase HPLC (gradient: 20-80% [aqueous acetonitrile + 1% trifluoroacetic acid] over 20mins). LCMS: $R_T = 4.40$ minutes; MS: $555(M)^+$, $553(M)^-$.

(b) By proceeding in a similar manner to Example 5(a) but using 2-methoxyphenyl-isothiocyanate in Step 8 there was prepared (R,S) 3-(4-{2-[2-(2-methoxy-phenylamino)-benzoxazol-6-yl]-acetyl-amino}-phenyl)-3-[(5-methylisoxazole-3-carbonyl)-amino]-propionic acid.

LCMS R_T = 4.45 minutes; MS: 571(M)⁺, 569(M)⁻.

5

(c) By proceeding in a similar manner to Example 5(a) but using 2-chlorophenyl-isothiocyanate in Step 8 there was prepared (R,S) 3-(4-{2-[2-(2-chloro-phenylamino)-benzoxazol-6-yl]-acetyl-amino}-phenyl)-3-[(5-methylisoxazole-3-carbonyl)-amino]-propionic acid. LCMS R_T

= 4.55 minutes; MS: 575(M)⁺, 573(M)⁻.

10

(d) By proceeding in a similar manner to Example 5(a) but using phenylisothiocyanate in Step 8 there was prepared (R,S) 3-(4-{2-[2-(phenylamino)-benzoxazol-6-yl]-acetyl-amino}-phenyl)-3-[(5-methylisoxazole-3-carbonyl)-amino]-propionic acid. LCMS R_T = 4.43 minutes;

MS: 541(M)⁺, 539(M)⁻.

15

(e) By proceeding in a similar manner to Example 5(a) but using 2-pyridylisothiocyanate in Step 8 there was prepared (R,S) 3-(4-{2-[2-(2-pyridylamino)-benzoxazol-6-yl]-acetyl-amino}-phenyl)-3-[(5-methylisoxazole-3-carbonyl)-amino]-propionic acid. LCMS R_T = 3.83 minutes;

MS: 542(M)⁺, 540(M)⁻.

20

(f) By proceeding in a similar manner to Example 5(a) but using morpholinoacetic acid in Step 3 there was prepared (R,S) 3-(4-{2-[2-(2-methyl-phenylamino)-benzoxazol-6-yl]-acetyl-amino}-phenyl)-3-[(morpholinoacetyl)-amino]-propionic acid. LCMS R_T = 3.57 minutes;

MS: 572(M)⁺, 570(M)⁻.

25

(g) By proceeding in a similar manner to Example 5(a) but using isonicotinic acid in Step 3 and 2-methoxyphenyl-isothiocyanate in Step 8 there was prepared (R,S) 3-(4-{2-[2-(2-methoxy-phenylamino)-benzoxazol-6-yl]-acetyl-amino}-phenyl)-3-[(pyridine-4-carbonyl)-amino]-propionic acid. LCMS R_T = 4.23 minutes; MS: 566(M)⁺, 564(M)⁻.

30

(h) By proceeding in a similar manner to Example 5(a) but using isonicotinic acid in Step 3 and 2-chlorophenyl-isothiocyanate in Step 8 there was prepared (R,S) 3-(4-{2-[2-(2-chloro-

phenylamino)-benzoxazol-6-yl]-acetyl-amino}-phenyl)-3-[(pyridine-4-carbonyl)-amino]-propionic acid. LCMS R_T = 4.32 minutes; MS: 570(M)⁺, 568(M)⁻.

(i) By proceeding in a similar manner to Example 5(a) but using isonicotinic acid in Step 3 and 3-methoxyphenyl-isothiocyanate in Step 8 there was prepared (R,S) 3-(4-{2-[2-(3-methoxy-phenylamino)-benzoxazol-6-yl]-acetyl-amino}-phenyl)-3-[(pyridine-4-carbonyl)-amino]-propionic acid. LCMS R_T = 4.23 minutes; MS: 566(M)⁺, 564(M)⁻.

(j) By proceeding in a similar manner to Example 5(a) but using isonicotinic acid in Step 3 and phenyl-isothiocyanate in Step 8 there was prepared (R,S) 3-(4-{2-[2-(phenylamino)-benzoxazol-6-yl]-acetyl-amino}-phenyl)-3-[(pyridine-4-carbonyl)-amino]-propionic acid. LCMS R_T = 4.18 minutes; MS: 536(M)⁺, 534(M)⁻.

(k) By proceeding in a similar manner to Example 5(a) but using isonicotinic acid in Step 3 and 2-pyridylisothiocyanate in Step 8 there was prepared (R,S) 3-(4-{2-[2-(2-pyridylamino)-benzoxazol-6-yl]-acetyl-amino}-phenyl)-3-[(pyridine-4-carbonyl)-amino]-propionic acid. LCMS R_T = 3.42 minutes; MS: 537(M)⁺, 535(M)⁻.

(l) By proceeding in a similar manner to Example 5(a) but using thiophene-2-carboxylic acid in Step 3 there was prepared (R,S) 3-(4-{2-[2-(2-methyl-phenylamino)-benzoxazol-6-yl]-acetyl-amino}-phenyl)-3-[(thiophene-2-carbonyl)-amino]-propionic acid. LCMS R_T = 4.38 minutes; MS: 555(M)⁺, 554(M)⁻.

REFERENCE EXAMPLE 1

2-o-Tolylamino-benzoxazole-6-acetic acid

A mixture of ethyl 4-amino-3-hydroxy-phenylacetate (3.3g, Reference Example 2) and o-tolylisothiocyanate (2.5mL) in ethanol (150mL) was stirred at room temperature for about 2 hours. After standing at room temperature overnight the mixture was evaporated and the residue was subjected to flash chromatography on silica eluting with a mixture of pentane and ethyl acetate (7:3, v/v) to give a yellow foam. A solution of this material in ethanol (150mL) was treated with dicyclohexylcarbodiimide (3.0g) and the mixture was heated at reflux temperature for 2 hours. The mixture was evaporated and the residue subjected to short column chromatography on silica eluting with a mixture of 5-10% tert-butyl methyl ether in dichloromethane to remove dicyclohexylurea. The resulting light yellow oil was dissolved in

ethanol (100mL) and the solution was treated with sodium hydroxide solution (15mL, 1M) then heated at reflux temperature for 2 hours. The reaction mixture was evaporated and the residue was dissolved in water. The solution was washed with ethyl acetate and the aqueous layer was acidified to pH 1 by addition of concentrated hydrochloric acid. The resulting white precipitate was collected by filtration, then washed thoroughly with water, and then dried to give the title compound (1.8g) as a white solid.

REFERENCE EXAMPLE 2

Ethyl 4-amino-3-hydroxy-phenylacetate

A solution of ethyl 3-hydroxy-4-nitrophenylacetate (5.0g, Reference Example 3) was dissolved in ethanol (approximately 200mL) was treated with ammonium formate (approximately 20g). The mixture was warmed to 50°C and then treated cautiously with palladium on charcoal (approximately 1g, 5%) - effervescence was observed. After 30 minutes the mixture was filtered hot through a pad of celite and the filtrate was concentrated to give the title compound (3.3 g) as a black solid.

REFERENCE EXAMPLE 3

Ethyl 3-hydroxy-4-nitrophenylacetate

A solution of 3-hydroxy-4-nitrophenylacetic acid (4.0g, prepared according to the procedure described by Meyer et al, J.Med.Chem., 1997, 40, pages 1049-1062) in ethanol (approximately 100mL) was treated with concentrated hydrochloric acid (5-8 drops) was heated at reflux temperature for 3 hours then evaporated. The residue was dissolved in tert-butyl methylether and the solution was washed with saturated aqueous sodium bicarbonate solution, then with water, then dried, and then evaporated to give the title compound (5.0g) as a light yellow solid.

REFERENCE EXAMPLE 4

[R]-tert-Butyl 3-(acetylmethylamino)-3-[(4-methylamino)phenyl]propionate

[R]-tert-butyl 3-(acetylmethylamino)-3-[(4-(N-tertiary-butyloxycarbonyl-N-methylamino)phenyl]propionate (4.3g, Reference Example 5) was dissolved in a 5% solution of trifluoroacetic acid in dichloromethane (200mL) at room temperature and the reaction followed by TLC analysis. When reaction was complete by TLC (about 1.5 hours) the mixture was poured cautiously onto a mixture of dichloromethane (100mL) and saturated aqueous sodium bicarbonate solution (200mL). The organic layer was dried and then evaporated to give the title compound (3.9g) as a yellow oil which slowly crystallised on standing.

REFERENCE EXAMPLE 5**[R]-tert-Butyl 3-(acetylmethylamino)-3-[(4-(N-tertiary-butyloxycarbonyl-N-methylamino)phenyl]propionate**

5 A stirred solution of [R]-tert-butyl 3-(methylamino)-3-[(4-(N-tertiary-butyloxycarbonyl-N-methylamino)phenyl]propionate (6.0g, Reference Example 6) in tetrahydrofuran (100mL) was treated with triethylamine (5.4g) and then with acetyl chloride (2.12g) dropwise (an immediate precipitate was formed). The mixture was stirred for a further 30 minutes, then partitioned between ethyl acetate (200mL) and hydrochloric acid (100mL, 1M). The organic layer was washed with aqueous sodium bicarbonate solution (5%) then dried and then evaporated to give
10 the title compound (4.3g) as a yellow oil.

REFERENCE EXAMPLE 6**[R]-tert-Butyl 3-(methylamino)-3-[(4-(N-tertiary-butyloxycarbonyl-N-methylamino)phenyl]propionate**

15 A solution of tert-butyl 3(R)-[N-methyl-N-((S)1-phenylethyl)amino]-3-[(4-(N-tertiary-butyloxycarbonyl-N-methylamino)phenyl]propionate (6.5g, Reference Example 7) in ethanol (50mL), warmed to 60°C, was treated with formic acid (4mL) then with 10% palladium on charcoal (2g). After stirring at 60°C for one hour the reaction mixture was allowed to cool to room temperature then filtered thorough filter-aid to remove the spent catalyst. The filtrate was
20 evaporated to low bulk and the residue was partitioned between ethyl acetate and aqueous sodium bicarbonate solution (200mL, 5%). The organic layer was dried and then evaporated to give the title compound (6.0g) as a colourless oil.

REFERENCE EXAMPLE 7

25 **tert-Butyl 3(R)-[N-methyl-N-((S)1-phenylethyl)amino]-3-[(4-(N-tertiary-butyloxycarbonyl-N-methylamino)phenyl]propionate**

A stirred solution of (S) N-methyl-N-(1-phenylethyl)amine (9.8g) was dissolved in tetrahydrofuran (60mL), under a nitrogen atmosphere and cooled to below - 70°C, was treated dropwise with a solution of butyllithium in hexanes (11.3mL, 2.5M). After about 10 minutes the
30 mixture was treated dropwise with a solution of tert-butyl 4-(N-tertiary-butyloxycarbonyl-N-methylamino)cinnamate (4.7g, Reference Example 8) in tetrahydrofuran (40mL) over 20 minutes. The reaction mixture was stirred for a further 20 minutes then poured onto a mixture of ethyl acetate (500mL) and brine (500mL). The organic layer was dried and then evaporated. The residue was subjected to flash chromatography on silica eluting with a mixture of ethyl
35 acetate and cyclohexane (7:3, v/v) to give the title compound (6.5g) as a colourless oil.

REFERENCE EXAMPLE 8**tert-Butyl 4-(N-tertiary-butyloxycarbonyl-N-methylamino)cinnamate**

A mixture of N-tertiary-butyloxycarbonyl-N-methyl-4-iodoaniline (11g, Reference Example 9),
5 tert-butyl acrylate (8.4g), tris-(o-tolyl)phosphine (500mg), palladium (II) acetate (150mg), and
triethylamine (7g) in DMF (20mL) was stirred at 90°C under nitrogen overnight. The reaction
mixture was cooled to room temperature then partitioned between ethyl acetate (500mL) and
hydrochloric acid solution (500mL, 1M). The organic phase was dried and then evaporated. The
residue was crystallised from cyclohexane to give the title compound (7.4g) as a white solid.

REFERENCE EXAMPLE 9**N-tertiary-Butyloxycarbonyl-N-methyl-4-iodoaniline**

A solution of N-tertiary-butyloxycarbonyl-4-iodoaniline (11.5g, see PG Ciattini et al, Tet. Lett,
1995, 36, 4133-4136 for preparation) in dimethylformamide (70mL), under nitrogen, was treated
15 portionwise with sodium hydride (1.6g, 60% dispersion in mineral oil). When effervescence had
ceased (after about 5 minutes) the mixture was treated with methyl iodide and stirring was
continued at room temperature for 2 hours. The reaction mixture was partitioned between ethyl
acetate (500mL) and water (500mL). The organic phase was dried and then evaporated to give
the title compound (11.5g) as a pink oil.

REFERENCE EXAMPLE 10

(a) **(R) 3-(4-Amino-phenyl)-3-[(5-methyl-isoxazole-3-carbonyl)-amino]-propionic acid tert-butyl ester**

A solution of (R) 3-(4-tert-butoxycarbonylamino-phenyl)-3-[(5-methyl-isoxazole-3-carbonyl)-
25 amino]-propionic acid tert-butyl ester (2g, Reference Example 11) in dichloromethane (50mL)
was treated with trifluoroacetic acid (5mL). After four hours [the reaction was monitored by
TLC: no more starting material was visible after about 4 hours] at room temperature the
reaction mixture was poured carefully onto a mixture of sodium hydrogen carbonate solution
(100mL, 5% w/v) and dichloromethane (50mL). The organic layer was separated then dried and
30 then evaporated to give the title compound (1.0g) as a yellow oil which slowly crystallised on
standing.

(b) By proceeding in a similar manner to that described in Reference Example 10(a) but
using (R) methyl 3-(4-tert-butoxycarbonylamino-phenyl)-3-[4-methoxycarbonylbutanoyl-amino]-
35 propionate (Reference Example 13) there was prepared (R) methyl 3-(4-amino-phenyl)-3-[4-
methoxycarbonylbutanoyl-amino]-propionate as an amber coloured oil.

REFERENCE EXAMPLE 11

(R) 3-(4-tert-Butoxycarbonylamino-phenyl)-3-[(5-methyl-isoxazole-3-carbonyl)-amino]-propionic acid tert-butyl ester

- 5 A solution of (R) 3-Amino-3-(4-tert-butoxycarbonylamino-phenyl)-propionic acid tert-butyl ester (2.0g), 5-methyl-isoxazole-3-carboxylic acid (890 mg), and O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (2.66g) in dimethylformamide (20mL) was treated with diisopropylethylamine (1.8g). After standing at room temperature for 1 hour the mixture was partitioned between ethyl acetate (100mL) and hydrochloric acid (100mL, 1M). The
10 organic layer was washed with sodium hydrogen carbonate solution (100mL, 5% w/v), then dried and then evaporated. The residue was triturated with the minimum volume of ether to give the title compound (2.0g) as a white solid.

REFERENCE EXAMPLE 12

- 15 **Methyl 4-(2-methoxycarbonyl-1-[4-[2-(2-o-tolylamino-benzoxazol-5-yl)-acetyl-amino]-phenyl]-ethylcarbamoyl)-butyrate**

- A mixture of 2-o-tolylamino-benzoxazole-6-acetic acid (0.5g, Reference Example 1), O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (1g), dimethylformamide (40mL), diisopropylethylamine (1.5mL) and (R) methyl 3-(4-amino-phenyl)-
20 3-[4-methoxycarbonylbutanoyl-amino]-propionate [0.57g, Reference Example 10(a)] was stirred at room temperature for 2.5 hours, then left for 4 days and then evaporated. The residue was dissolved in ethyl acetate and the solution was washed well with water and then evaporated. The resulting yellow foam was subjected to short column chromatography on silica eluting with a mixture of dichloromethane and methanol (19:1, v/v) followed by trituration with ethanol to
25 give the title compound (0.31g) as a colourless solid.

REFERENCE EXAMPLE 13

(R) Methyl 3-(4-tert-butoxycarbonylamino-phenyl)-3-[4-methoxycarbonylbutanoyl-amino]-propionate

- 30 A solution of (R) 3-Amino-3-(4-tert-butoxycarbonylamino-phenyl)-propionic acid methyl ester (4.5g) and triethylamine (2.65mL) in dichloromethane (35mL) was treated dropwise with methyl 4-(chloroformyl)butyrate (2.21mL). After stirring at room temperature for 2 hours the reaction mixture was treated with water and then extracted with ethyl acetate. The extract was washed with water, then dried and then evaporated to give the title compound as an oil which was used
35 without further purification.

IN VITRO AND IN VIVO TEST PROCEDURES

1. Inhibitory effects of compounds on VLA4 dependent cell adhesion to Fibronectin and VCAM.

1.1 Metabolic labelling of RAMOS cells.

RAMOS cells (a pre-B cell line from ECACC, Porton Down, UK) are cultured in RPMI culture medium (Gibco, UK) supplemented with 5% foetal calf serum (FCS, Gibco, UK). Prior to assay the cells are suspended at a concentration of 0.5×10^6 cells/ml RPMI and labelled with $400\mu\text{Ci}/100\text{ml}$ s of [^3H]-methionine (Amersham, UK) for 18 hours at 37°C .

1.2 96 well plate preparation for adhesion assay.

Cytostar plates (Amersham, UK) were coated with $50\mu\text{l}/\text{well}$ of either $3\mu\text{g}/\text{ml}$ human soluble VCAM-1 (R&D Systems Ltd, UK) or $28.8\mu\text{g}/\text{ml}$ human tissue Fibronectin (Sigma, UK). In control non-specific binding wells $50\mu\text{l}$ phosphate buffered saline was added. The plates were then left to dry in an incubator at 25°C , overnight. The next day the plates were blocked with $200\mu\text{l}/\text{well}$ of Pucks buffer (Gibco, UK) supplemented with 1% BSA (Sigma, UK). The plates were left at room temperature in the dark for 2 hours. The blocking buffer was then disposed of and the plates dried by inverting the plate and gently tapping it on a paper tissue. $50\mu\text{l}/\text{well}$ of 3.6% dimethyl sulphoxide in Pucks buffer supplemented with 5mM manganese chloride (to activate the integrin receptor Sigma, UK) and 0.2% BSA (Sigma, UK), was added to the appropriate control test binding and non-specific binding assay wells in the plate. $50\mu\text{l}/\text{well}$ of the test compounds at the appropriate concentrations diluted in 3.6% dimethyl sulphoxide in Pucks buffer supplemented with 5mM manganese chloride and 0.2% BSA, was added to the test wells.

Metabolically labelled cells were suspended at 4×10^6 cells/ml in Pucks buffer that was supplemented with manganese chloride and BSA as above. $50\mu\text{l}/\text{well}$ of cells in 3.6% dimethyl sulphoxide in Pucks buffer and supplements was added to all plate wells.

The same procedure exists for plates coated with either VCAM-1 or fibronectin and data is determined for compound inhibition of cell binding to both substrates.

1.3 Performance of assay and data analysis.

The plates containing cells in control or compound test wells are incubated in the dark at room temperature for 1 hour.

The plates are then counted on a Wallac Microbeta scintillation counter (Wallac, UK) and the captured data processed in Microsoft Excel (Microsoft, US). The data was expressed as an IC₅₀, namely the concentration of inhibitor at which 50% of control binding occurs. The percentage binding is determined from the equation:

$$\{[(C_{TB} - C_{NS}) - (C_I - C_{NS})] / (C_{TB} - C_{NS})\} \times 100 = \% \text{ binding}$$

where C_{TB} are the counts bound to fibronectin (or VCAM-1) coated wells without inhibitor present, C_{NS} are the counts present in wells without substrate, and C_I are the counts present in wells containing a cell adhesion inhibitor.

Compound data of this invention is expressed for IC₅₀s for inhibition of cell adhesion to both fibronectin and VCAM-1. Particular compounds of the invention inhibit cell adhesion to fibronectin and VCAM-1 with IC₅₀s in the range 100 micromolar to 1 nanomolar. Preferred compounds of the invention inhibit cell adhesion to fibronectin and VCAM-1 with IC₅₀s in the range 10 nanomolar to 1 nanomolar.

2. Inhibition of antigen-induced airway inflammation in the mouse and rat.

2.1 Sensitization of the animals.

Rats (Brown Norway, Harland Olac, UK) are sensitized on days 0, 12 and 21 with ovalbumin (100 µg, intraperitoneally [i.p], Sigma, UK) administered with aluminium hydroxide adjuvant (100mg, i.p., Sigma, UK) in saline (1ml, i.p.).

In addition mice (C57) are sensitized on days 0 and 12 with ovalbumin (10µg, i.p.) administered with aluminium hydroxide adjuvant (20mg, i.p.) in saline (0.2ml, i.p.).

2.2 Antigen challenge.

Rats are challenged on any one day between days 28-38, while mice are challenged on any one day between days 20-30.

The animals are challenged by exposure for 30 minutes (rats) or 1 hour (mice) to an aerosol of ovalbumin (10g / l) generated by an ultrasonic nebulizer (deVilbiss Ultraneb, US) and passed into an exposure chamber.

2.3 Treatment protocols.

Animals are treated as required before or after antigen challenge. The aqueous-soluble compounds of this invention can be prepared in water (for oral, p.o. dosing) or saline (for intratracheal, i.t. dosing). Non-soluble compounds are prepared as suspensions by grinding and sonicating the solid in 0.5 % methyl cellulose / 0.2 % polysorbate 80 in water (for p.o. dosing, both Merck UK Ltd., UK) or saline (for i.t. dosing). Dose volumes are: for rats 1ml / kg, p.o. or 0.5mg / kg, i.t.; for mice 10ml / kg, p.o. or 1ml / kg, i.t.

2.4 Assessment of airway inflammation.

The cell accumulation in the lung is assessed 24 hours after challenge (rats) or 48-72 hours after challenge (mice). The animals are euthanized with sodium pentobarbitone (200mg/kg, i.p., Pasteur Merieux, France) and the trachea is immediately cannulated. Cells are recovered from the airway lumen by bronchoalveolar lavage (BAL) and from the lung tissue by enzymatic (collagenase, Sigma, UK) disaggregation as follows.

BAL is performed by flushing the airways with 2 aliquots (each 10 ml/kg) RPMI 1640 medium (Gibco, UK) containing 10 % fetal calf serum (FCS, Serotec Ltd., UK). The recovered BAL aliquots are pooled and cell counts made as described below.

Immediately after BAL, the lung vasculature is flushed with RPMI 1640 / FCS to remove the blood pool of cells. The lung lobes are removed and cut into 0.5 mm pieces. Samples (rats: 400mg; mice: 150mg) of homogenous lung tissue are incubated in RPMI 1640 / FCS with collagenase (20 U/ml for 2 hours, then 60 U/ml for 1 hour, 37°C) to disaggregate cells from the tissue. Recovered cells are washed in RPMI 1640 / FCS.


Counts of total leukocytes recovered from the airway lumen and the lung tissue are made with an automated cell counter (Cobas Argos, US). Differential counts of eosinophils, neutrophils and mononuclear cells are made by light microscopy of cytocentrifuge preparations stained with Wright-Giemsa stain (Sigma, UK). T cells are counted by flow cytometry (EPICS XL, Coulter Electronics, US) using fluophore-labelled antibodies against CD2 (a pan-T cell marker used to quantify total T cells), CD4, CD8 and CD25 (a marker of activated T cells). All antibodies were supplied by Serotec Ltd., UK)

2.5 Data analysis.

The cell data was expressed as mean cell numbers in unchallenged, challenged and vehicle treated, and challenged and compound treated groups, including the standard error of the means. Statistical analysis of the difference among treatment groups was evaluated using one-way analysis of variance via the Mann-Whitney test. Where $p < 0.05$ no statistical significance existed.

CLAIMS

1. A compound of general formula (I):-



wherein:-

Het represents a saturated, partially saturated or fully unsaturated 8 to 10 membered bicyclic ring system containing at least one heteroatom selected from O, S or N, optionally substituted by one or more aryl group substituents;

R^1 represents aryl, heteroaryl, optionally substituted alkyl, alkenyl or alkynyl where each is optionally substituted by R^3 , $-Z^2R^4$, $-Z^3H$, $-C(=O)-R^4$, $-NR^5-C(=Z^3)-R^4$, $-NR^5-C(=O)-OR^4$, $-NR^5-SO_2-R^4$, $-SO_2-NY^1Y^2$, $-NY^1Y^2$ or $-C(=Z^3)-NY^1Y^2$; or cycloalkyl or heterocycloalkyl, each optionally substituted by R^4 , $-Z^2R^4$, $-Z^3H$, $-C(=O)-R^4$, $-NR^5-C(=Z^3)-R^4$, $-NR^5-C(=O)-OR^4$, $-NR^5-SO_2-R^4$, $-SO_2-NY^1Y^2$, $-NY^1Y^2$ or $-C(=Z^3)-NY^1Y^2$;

R^2 represents hydrogen, halogen, lower alkyl or lower alkoxy;

R^3 represents aryl, cycloalkyl, cycloalkenyl, heteroaryl, or heterocycloalkyl;

R^4 represents alkyl, alkenyl, alkynyl, aryl, arylalkyl, arylalkenyl, arylalkynyl, cycloalkyl, cycloalkylalkyl, cycloalkenyl, cycloalkenylalkyl, heteroaryl, heteroarylalkyl, heteroarylalkenyl, heteroarylalkynyl, heterocycloalkyl or heterocycloalkylalkyl;

R^5 represents hydrogen or lower alkyl;

R^6 is an alkylene chain, an alkenylene chain or an alkynylene chain;

R^7 is a direct bond, cycloalkylene, heterocycloalkylene, aryldiyl, heteroaryldiyl, $-C(=Z^3)-NR^5$ -, $-NR^5-C(=Z^3)-$, $-Z^3$ -, $-C(=O)-$, $-C(=NOR^5)-$, $-NR^5$ -, $-NR^5-C(=Z^3)-NR^5$ -, $-SO_2-NR^5$ -, $-NR^5-SO_2$ -, $-O-C(=O)-$, $-C(=O)-O-$, $-NR^5-C(=O)-O-$ or $-O-C(=O)-NR^5$ -;

R^8 is hydrogen, alkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, heterocycloalkyl or heterocycloalkylalkyl;

R^9 is alkyl, aryl, cycloalkyl, heteroaryl or heterocycloalkyl, or alkyl substituted by aryl, an acidic functional group or corresponding protected derivative, cycloalkyl, heteroaryl, heterocycloalkyl, $-Z^3H$, $-Z^2R^4$, $-C(=O)-NY^3Y^4$ or $-NY^3Y^4$;

L^1 represents a $-R^6-R^7$ - linkage;

- 5 L^2 represents an alkylene chain substituted by hydroxy, oxo, $-OR^4$, $-O-C(=O)-R^4$, $-N(R^8)-C(=O)-R^9$, $-N(R^8)-C(=O)-OR^9$, $-N(R^8)-SO_2-R^9$, or $-NY^3Y^4$;

Y is carboxy or an acid bioisostere;

Y^1 and Y^2 are independently hydrogen, alkenyl, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl or heteroarylalkyl; or the group $-NY^1Y^2$ may form a cyclic amine;

- 10 Y^3 and Y^4 are independently hydrogen, alkenyl, alkyl, alkynyl, aryl, cycloalkenyl, cycloalkyl, heteroaryl, heterocycloalkyl, or alkyl substituted by alkoxy, aryl, cyano, cycloalkyl, heteroaryl, heterocycloalkyl, hydroxy, oxo, $-NY^1Y^2$, or one or more $-CO_2R^8$ or $-C(=O)-NY^1Y^2$ groups; or the group $-NY^3Y^4$ may form a cyclic amine;

Z^1 represents NR^5 ;

- 15 Z^2 is O or $S(O)_n$;



Z^3 is O or S; and

n is zero or an integer 1 or 2;

and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and prodrugs; but excluding compounds where



- 20 an oxygen, nitrogen or sulphur atom is attached directly to a carbon carbon multiple bond of an alkenyl or alkynyl residue.


2. A compound according to claim 1 in which Het represents , wherein ring

 is a 5 or 6 membered heterocycle and ring  is a 5 or 6 membered fully

- 25 unsaturated heterocycle or a benzene ring, each ring optionally substituted, and the two rings are joined together by a carbon-carbon linkage or a carbon-nitrogen linkage.


3. A compound according to claim 2 in which Het represents an optionally substituted 9

membered bicyclic system  in which ring  is a 5 membered fully

unsaturated heterocycle,  is an optionally substituted benzene and the two rings are

joined together by carbon atom linkages.

4. A compound according to claim 3 in which Het represents optionally substituted benzoxazolyl in which the benzene ring contains the optional substituent.

5. A compound according to any preceding claim in which ring  is a benzene ring

optionally substituted by one of C₁₋₄ alkyl, C₁₋₄ alkoxy, amino, halogen, hydroxy, C₁₋₄ alkylthio, C₁₋₄ alkylsulphinyl, C₁₋₄ alkylsulphonyl, nitro or trifluoromethyl.

6. A compound according to any preceding claim in which R¹ represents optionally substituted phenyl.

7. A compound according to any preceding claim in which Z¹ represents NH.

8. A compound according to any preceding claim in which L¹ represents a -R⁶-R⁷- linkage where R⁶ is a straight or branched C₁₋₄alkylene chain and R⁷ represents -C(=O)-NR⁵- where

R⁵ is hydrogen or C₁₋₄ alkyl.

9. A compound according to claim 8 in which R⁶ is methylene.

10. A compound according to claim 8 in which L¹ represents -CH₂C(=O)-NH-.

11. A compound according to any preceding claim in which R² represents hydrogen, C₁₋₄ alkyl or C₁₋₄ alkoxy.

12. A compound according to claim 11 in which R^2 represents hydrogen.

13. A compound according to any preceding claim in which L^2 represents a straight or
5 branched C_{1-4} alkylene linkage substituted by $-N(R^8)-C(=O)-R^9$, $-N(R^8)-C(=O)-OR^9$,
 $-N(R^8)-SO_2-R^9$ or $-NY^3Y^4$.

14. A compound according to claim 13 in which L^2 represents ethylene substituted by
 $-N(R^8)-C(=O)-R^9$, $-N(R^8)-C(=O)-OR^9$, $-N(R^8)-SO_2-R^9$ or $-NY^3Y^4$.

10


15. A compound according to claim 14 in which L^2 represents $\begin{array}{c} \text{---CH---CH}_2\text{---} \\ | \\ R^{11} \end{array}$ where R^{11} is
 $-N(R^8)-C(=O)-R^9$, $-N(R^8)-C(=O)-OR^9$, $-N(R^8)-SO_2-R^9$, or $-NY^3Y^4$.

16. A compound according to claim 15 in which L^2 represents $\begin{array}{c} \text{---CH---CH}_2\text{---} \\ | \\ R^{11} \end{array}$ where R^{11} is
15 $-N(R^8)-C(=O)-R^9$, $-N(R^8)-C(=O)-OR^9$, $-N(R^8)-SO_2-R^9$, or $-NY^3Y^4$.

17. A compound according to any preceding claim in which Y is carboxy.

18. A compound of formula (Ia):-

20




(Ia)

in which R^1 , R^2 , R^5 , R^6 , L^2 , Y and Z^1 are as defined in any preceding claim, R^{12} is hydrogen,
acyl, acylamino, alkoxy, alkoxy carbonyl, alkylendioxy, alkylsulphinyl, alkylsulphonyl, alkylthio,
25 aroyl, aroylamino, aryl, arylalkyloxy, arylalkyloxycarbonyl, arylalkylthio, aryloxy,
aryloxycarbonyl, arylsulphinyl, arylsulphonyl, arylthio, carboxy, cyano, halo, heteroaroyl,
heteroaryl, heteroarylalkyloxy, heteroaroylamino, heteroaryloxy, hydroxy, nitro,

trifluoromethyl, Y^1Y^2N- , Y^1Y^2NCO- , $Y^1Y^2NSO_2-$, $Y^1Y^2N-C_{2-6}alkylene-Z-$, $alkylC(=O)-Y^1N-$, $alkylSO_2-Y^1N-$ or alkyl optionally substituted with aryl, heteroaryl, hydroxy, or Y^1Y^2N- , and X is O, and their prodrugs and pharmaceutically acceptable salts, and solvates of compounds of formula (Ia) and their prodrugs.

19. A compound according to claim 18 in which R^{12} represents hydrogen, C_{1-4} alkyl or C_{1-4} alkoxy.

20. A compound according to claim 18 or claim 19 in which the group



21. A pharmaceutical composition comprising an effective amount of a compound according to claim 1 or a corresponding N-oxide or prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an N-oxide prodrug thereof, in association with a pharmaceutically acceptable carrier or excipient.

22. A compound according to claim 1 or a corresponding N-oxide or prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an N-oxide or prodrug thereof, for use in therapy.

23. A compound according to claim 1 or a corresponding N-oxide or prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an N-oxide or prodrug thereof, for use in the treatment of a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of $\alpha 4\beta 1$ mediated cell adhesion.

24. A composition according to claim 21 for use in the treatment of a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of $\alpha 4\beta 1$ mediated cell adhesion.

25. A compound or composition according to claim 1 or 21 respectively for use in the treatment of inflammatory diseases.

26. A compound or composition according to claim 1 or 21 respectively for use in the treatment of asthma.

5 27. Use of a compound according to claim 1 or a corresponding N-oxide or prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an N-oxide or prodrug thereof, in the manufacture of a medicament for the treatment of a patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of $\alpha 4\beta 1$ mediated cell adhesion.

10

28. Use of a compound according to claim 1 or a corresponding N-oxide or prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an N-oxide or prodrug thereof, in the manufacture of a medicament for the treatment of asthma.

15

29. A method for the treatment of a human or non-human animal patient suffering from, or subject to, conditions which can be ameliorated by the administration of an inhibitor of $\alpha 4\beta 1$ mediated cell adhesion comprising administering to said patient an effective amount of a compound according to claim 1 or a corresponding N-oxide or prodrug, or a pharmaceutically acceptable salt or solvate of such a compound or an N-oxide or prodrug thereof.

20

30. A compound as substantially hereinbefore described with references to the Examples.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/01731

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D263/58 C07D413/12 A61K31/42 //(C07D413/12,263:00, 263:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, WPI Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 97 36862 A (CLARE MICHAEL ;SEARLE & CO (US); CHEN BARBARA B (US); CHEN HELEN () 9 October 1997 (1997-10-09) 1st def. of A	1-30
A	WO 98 43962 A (DU PONT PHARM CO) 8 October 1998 (1998-10-08) formulas (Ie-Id)	1-30
A	WO 99 10312 A (HOFFMANN LA ROCHE) 4 March 1999 (1999-03-04) Formula (1) - X-7	1-30
A	WO 97 08145 A (DESAI BIPINCHANDRA NANUBHAI ;LINDMARK RICHARD JOHN (US); RUSSELL M) 6 March 1997 (1997-03-06) 1st def. of A	1-30
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

17 August 2000

Date of mailing of the international search report

30/08/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 00/01731

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	WO 99 23063 A (LAI JUSTINE YEUN QUAI ;MORLEY ANDREW DAVID (GB); RHONE POULENC ROR) 14 May 1999 (1999-05-14) abstract ----	1-30
A,P	WO 00 05224 A (BRITTAIN DAVID ROBERT ;DAVIES GARETH MORSE (GB); LARGE MICHAEL STE) 3 February 2000 (2000-02-03) abstract -----	1-30

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Present claims 1-17 relate to an extremely large number of possible compounds/products. In fact, these claims contain so many options, variants, possible permutations, etc, that a lack of CLARITY and CONCISENESS within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. A formula consisting virtually of variables (which are moreover in at least part of the claims ill-defined (e.g. the use of unspecified "aryl", "heterocyclic", etc, and derivatives thereof, "acidic functional group", "acid bioisostere") cannot be considered to be a clear and concise definition of patentable subject-matter. As a matter of principle, a formula consisting virtually completely of variables is hardly a permissible generalisation which is fairly based on experimental evidence. All potential novel and inventive subject-matter is hidden in this large amount of possible compounds. It must be made credible that essentially all of the claimed matter solves the problem underlying the application.

Furthermore the claimed subject-matter lacks a significant structural element qualifying as the special technical feature that clearly defines the very invention as a contribution over the art and that is common to all the claimed compounds. Presently the portion which is always present (a phenyl ring between the linkers L1 and L2) is so small that it is impossible to carry out a complete and meaningful search into the state of the art on the basis of these claims.

In the absence of sound and credible support, the claimed scope appears therefore to its broadest extent to be speculative: the scope of the claims is fully disproportionate to the specifically exemplified matter. Actual support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a small proportion of the compounds/products claimed. In the present case, the claims so lack SUPPORT, and the application so lacks DISCLOSURE, that a meaningful search over the whole of the claimed scope is impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clearly and concisely supported and disclosed, namely those parts relating to the compounds/products as claimed in claim 18 and dependent claims thereof and described in tables 1, 2 and 3.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/GB 00/01731

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claim 29 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat. Application No

PCT/GB 00/01731

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9736862 A	09-10-1997	AU 2337097 A CA 2250464 A EP 0889877 A JP 2000506538 T US 5773646 A	22-10-1997 09-10-1997 13-01-1999 30-05-2000 30-06-1998
WO 9843962 A	08-10-1998	AU 6780398 A	22-10-1998
WO 9910312 A	04-03-1999	AU 9262098 A EP 1005445 A NO 20000841 A ZA 9807604 A	16-03-1999 07-06-2000 21-02-2000 18-05-1999
WO 9708145 A	06-03-1997	AU 702487 B AU 7103996 A BR 9610422 A CA 2230209 A CN 1201454 A CZ 9800341 A EP 0850221 A JP 11510814 T NO 980817 A NZ 318926 A PL 325312 A	25-02-1999 19-03-1997 13-07-1999 06-03-1997 09-12-1998 16-09-1998 01-07-1998 21-09-1999 24-04-1998 29-04-1999 20-07-1998
WO 9923063 A	14-05-1999	AU 9755098 A EP 1027328 A NO 20002276 A	24-05-1999 16-08-2000 25-05-2000
WO 0005224 A	03-02-2000	AU 5053099 A	14-02-2000

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.